

Cenra Inc. and subsidiaries
Consolidated financial statements and Auditor's Report
Q2 2026 and 2025
(Stock Code: 3716)

Addresses: No.23, Hsiang Yang Rd., Taipei City 100

TEL: (02) 2312-4200

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

Centra Inc. and subsidiaries
Q2 2026 and 2025 Consolidated Financial Report and Independent Auditor's Review
Report
Table of Contents

Item	Page
1. Cover	1
2. Table of Contents	2 ~ 3
3. Report on Review of Financial Statements	4 ~ 5
4. Consolidated Balance Sheet	6 ~ 7
5. Consolidated comprehensive income statements	8 ~ 9
6. Consolidated statement of changes in equity	10
7. Consolidated cash flow statement	11 ~ 12
8. Notes to consolidated financial statement	13 ~ 70
(1) Company history	13
(2) Financial statements approval date and procedure	13
(3) Application of New Standards, Amendments and Interpretations	13 ~ 14
(4) Summary of significant accounting policies	15 ~ 16
(5) Critical accounting judgments, estimates and key sources of assumption uncertainty	17

Item	Page
(6) Summary of significant accounting titles	17 ~ 49
(7) Related party transactions	49 ~ 54
(8) Pledged assets	54
(9) Significant contingent liabilities and unrecognized contractual commitments	54 ~ 55
(10) Significant disaster loss	55
(11) Significant subsequent events	55
(12) Others	55 ~ 68
(13) Notes of disclosure	68
(14) Segment information	69 ~ 70

REPORT ON REVIEW OF FINANCIAL STATEMENTS TRANSLATED FROM CHINESE

To the Board of Directors and Stockholders of Cenra Inc.

Introduction

We have reviewed the accompanying consolidated balance sheets of Cenra Inc. and its subsidiaries (collectively referred to as the "Group") as of June 30, 2026 and 2025, and the related consolidated statements of comprehensive income for the three-month periods ended June 30, 2026 and 2025 and for the six-month periods ended June 30, 2026 and 2025, the consolidated statements of changes in equity and cash flows for the six-month periods then ended, and the related notes to the consolidated financial statements, including a summary of significant accounting policies.

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting," as endorsed and issued into effect by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of review

Except for the matter described in the Basis for Qualified Conclusion section, we conducted our reviews in accordance with Standard on Review Engagements 2410, "Review of Financial Statements." A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for qualified conclusion

As described in Note 4(3) to the consolidated financial statements, certain non-significant subsidiaries included in the accompanying consolidated financial statements were not reviewed by independent auditors. The total assets of these subsidiaries amounted to \$509,906 and \$562,110 as of June 30, 2026 and 2025, representing 4.14% and 4.55% of the consolidated total assets, respectively. The total liabilities amounted to \$356,356 and \$374,147, representing 7.66% and 7.53% of the consolidated total liabilities, respectively. The total comprehensive income (loss) of these subsidiaries amounted to (\$31,428), (\$21,128), (\$33,398) and (\$36,306) for the three-month periods ended June 30, 2026 and 2025 and the six-month periods ended June 30, 2026 and 2025, respectively, representing (16.51%), 36.46%, (8.43%) and (46.62%) of the consolidated total comprehensive income, respectively.

In addition, certain investments accounted for using the equity method by Cenra Inc. and subsidiaries, and the related information on investee companies disclosed in Note 13, were recognized and disclosed based on the investees' self-prepared financial statements for the corresponding periods, which were not reviewed by independent auditors. As of June 30, 2026 and 2025, the carrying amounts of such investments accounted for using the equity method were \$538,900 and \$490,146, respectively, representing 4.37% and 3.97% of the consolidated total assets, respectively. The shares of profit of associates and joint ventures accounted for using the equity method amounted to \$27,130, \$7,199, \$46,657 and \$17,157 for the three-month periods ended June 30, 2026 and 2025 and the six-month periods ended June 30, 2026 and 2025,

Qualified conclusion

Based on our reviews, except for the possible effects of such adjustments, if any, as might have been determined to be necessary had the financial statements of certain non-significant subsidiaries and investments accounted for using the equity method described in the Basis for Qualified Conclusion section been reviewed by independent auditors, nothing has come to our attention that caused us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of Cenra Inc. and its subsidiaries as of June 30, 2026 and 2025, and their consolidated financial performance for the three-month periods ended June 30, 2026 and 2025 and for the six-month periods ended June 30, 2026 and 2025, and their consolidated cash flows for the six-month periods then ended, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting,” as endorsed and issued into effect by the Financial Supervisory Commission.

Cenra Inc. and subsidiaries
Consolidated Balance Sheet
June 30, 2026, December 31 and June 30, 2025

Unit: NTD thousand

			June 30, 2026		December 31, 2025		June 30, 2025	
		Additional						
Assets		notes	Amount	%	Amount	%	Amount	%
Current assets								
1100	Cash and cash equivalents	6 (1)	\$ 659,756	5	\$ 729,497	6	\$ 684,064	6
1136	Financial assets measured at the amortized cost-current	6 (5)	-	-	-	-	88,414	1
1150	Notes receivable-net	6 (2)	245,281	2	333,986	3	391,849	3
1160	Notes Receivable-Related Parties- net	7	89,453	1	116,929	1	44,501	-
1170	Notes accounts, net	6 (2)	1,410,340	12	1,466,325	12	1,471,430	12
1180	Account receivables-Related Parties- net	7	26,042	-	40,982	-	48,303	1
1197	Finance lease receivables, net	6 (9)	655	-	647	-	-	-
1200	Other receivables		10,576	-	16,476	-	18,226	-
1210	Other receivables - related parties	7	263,116	2	189,359	1	276,995	2
1220	Current income tax asset		49,105	1	43,854	-	43,567	-
130X	Inventory	6 (3)	2,883,663	23	2,708,659	22	2,630,392	21
1470	Other current assets		132,268	1	111,483	1	82,961	1
11XX	Total current assets		5,770,255	47	5,758,197	46	5,780,702	47
Non-Current assets								
1517	The financial assets measured for the fair values through other comprehensive income-non-current	6 (4)	119,450	1	166,496	1	181,419	1
1535	Financial assets measured at the amortized cost-non-current	6 (5)	141,913	1	134,866	1	-	-
1550	Investment under the equity method	6 (6) and 7	1,465,669	12	1,428,849	12	1,452,689	12
1600	Property, plant, and equipment	6 (7) and 8	3,895,500	32	3,952,523	32	3,989,000	32
1755	Right-of-use assets	6 (8)	359,479	3	369,122	3	378,973	3
1760	Net amount of investment oriented real estate	8	114,718	1	114,082	1	110,918	1
1780	Intangible assets		40,613	-	10,215	-	10,873	-
1840	Deferred income tax assets		163,762	1	211,676	2	229,181	2
194D	Long-term finance lease receivables, net	6 (9)	3,162	-	3,492	-	-	-
1990	Other non-current assets- Other	6 (10) and 8	256,526	2	297,671	2	218,003	2
15XX	Total of Non-Current Assets		6,560,792	53	6,688,992	54	6,571,056	53
1XXX	Total assets		\$ 12,331,047	100	\$ 12,447,189	100	\$ 12,351,758	100

(Continued on next page)

Cenra Inc. and subsidiaries
Consolidated Balance Sheet
June 30, 2026, December 31 and June 30, 2025

Unit: NTD thousand

Liabilities and equity		Additional notes	June 30, 2026		December 31, 2025		June 30, 2025	
			Amount	%	Amount	%	Amount	%
Current liabilities								
2100	Shot-term borrowings	6 (11) and 8	\$ 2,027,201	17	\$ 2,007,743	16	\$ 1,879,551	15
2110	Short-term notes payable	6 (12)	30,000	-	380,000	3	377,000	3
2130	Contractual liability- current	6 (21)	42,629	-	39,937	-	32,409	-
2150	Payable notes		700	-	807	-	-	-
2170	Accounts payable	7	789,991	6	750,296	6	726,719	6
2200	Other payables	6 (13)	756,773	6	720,125	6	811,952	7
2230	Current Tax Liability		81,720	1	74,126	1	68,142	1
2280	Lease liabilities - current		58,694	1	54,789	-	51,002	-
2320	Current portion of long-term liabilities	6 (14) and 8	-	-	-	-	25,200	-
2365	Refund liability – liquidity	6 (21)	33,742	-	58,706	1	73,418	1
2399	Other current liabilities- other		16,319	-	13,091	-	19,128	-
21XX	Total current liabilities		3,837,769	31	4,099,620	33	4,064,521	33
Non-current liabilities								
2540	Long-term borrowings	6 (14) and 8	330,400	3	240,800	2	397,700	3
2570	Deferred tax liabilities		159,052	1	153,379	1	146,414	1
2580	Lease liabilities – non-current		289,693	3	302,766	3	311,770	3
2600	Other non-current liabilities	6 (8)	36,670	-	38,992	-	46,683	-
25XX	Total of non-current liabilities		815,815	7	735,937	6	902,567	7
2XXX	Total liabilities		4,653,584	38	4,835,557	39	4,967,088	40
Equity of the parent company								
	Capital stock	6 (17)						
3110	Common stock capital		1,497,656	12	1,497,656	12	1,490,405	12
	Capital surplus	6 (18)						
3200	Capital surplus		5,907,735	48	5,907,847	48	5,882,247	48
	Retained earnings	6 (19)						
3310	Legal reserve		35,723	-	11,362	-	11,362	-
3320	Special reserve		222,767	2	222,767	2	222,767	2
3350	Undistributed earnings		284,170	2	252,494	2	112,229	1
	Other equity	6 (20)						
3400	Other equity		(114,754)	(1)	(173,841)	(2)	(248,273)	(2)
3500	Treasury stock	6 (17)	(162,302)	(1)	(146,631)	(1)	(125,932)	(1)
31XX	Equity attributable to owners of the parent Company		7,670,995	62	7,571,654	61	7,344,805	60
36XX	Non-controlling interest		6,468	-	39,978	-	39,865	-
3XXX	Total equity		7,677,463	62	7,611,632	61	7,384,670	60
	Significant contingent liabilities and unrecognized contractual commitments	9						
	Significant subsequent events	11						
3X2X	Total Liabilities and Equity		\$ 12,331,047	100	\$ 12,447,189	100	\$ 12,351,758	100

Please refer to the notes enclosed in the consolidated financial reports that are an integral part of the consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation Manager: Wang, Hou-Kai Accounting Supervisor: Hiang, Hsien-Chieh
Representative: Wang Hsien, I-Chen

Cenra Inc. and subsidiaries
Consolidated comprehensive income statements
January 1 to June 30, 2026 and 2025

Unit: NTD thousand
(except EPS in NTD)

	Item	Additional notes	April 1 to June 30, 2026		April 1 to June 30, 2025		January 1 to June 30, 2026		January 1 to June 30, 2025	
			Amount	%	Amount	%	Amount	%	Amount	%
4000	Operating revenues	6 (21) and 7	\$ 2,000,059	100	\$ 2,107,036	100	\$ 4,228,916	100	\$ 4,362,664	100
5000	Operating cost	6 (3) (25) and 7	(1,218,056)	(61)	(1,304,404)	(62)	(2,540,693)	(60)	(2,660,524)	(61)
5950	Operating gross profit		782,003	39	802,632	38	1,688,223	40	1,702,140	39
	Operating expenses	6 (25)								
6100	Marketing expenses		(463,386)	(23)	(493,670)	(23)	(927,240)	(22)	(1,028,778)	(24)
6200	Administrative expenses		(106,847)	(6)	(87,303)	(4)	(226,701)	(5)	(195,168)	(4)
6300	Research and development expenses		(123,126)	(6)	(116,461)	(6)	(239,932)	(6)	(246,871)	(6)
6450	Expected credit impairment gain (loss)	12 (2)	(6,229)	-	595	-	(4,449)	-	22,534	1
6000	Total operating expenses		(699,588)	(35)	(696,839)	(33)	(1,398,322)	(33)	(1,448,283)	(33)
6900	Operating income		82,415	4	105,793	5	289,901	7	253,857	6
	Non-operating revenues and expenses									
7100	Interest income	6 (22) and 7	3,222	-	2,881	-	5,501	-	5,198	-
7010	Other income	6 (23)	122,175	6	9,602	1	132,381	3	14,773	-
7020	Other profits and losses	6 (24)	(13,849)	(1)	(4,861)	-	(14,534)	-	(3,890)	-
7050	Financial costs	6 (26)	(13,690)	-	(15,347)	(1)	(28,833)	(1)	(31,172)	(1)
7060	Shareholding in the affiliated companies and joint ventures under the equity method	6 (6)	31,535	2	(14,252)	(1)	69,223	2	(7,321)	-
7000	Total non-operating revenues and expenses		129,393	7	(21,977)	(1)	163,738	4	(22,412)	(1)
7900	Net profit before taxation		211,808	11	83,816	4	453,639	11	231,445	5
7950	Income tax expenses	6 (27)	(30,053)	(2)	(36,670)	(2)	(78,895)	(2)	(66,084)	(1)
8200	Net income		\$ 181,755	9	\$ 47,146	2	\$ 374,744	9	\$ 165,361	4

(Continued on next page)

Cenra Inc. and subsidiaries
Consolidated comprehensive income statements
January 1 to June 30, 2026 and 2025

Unit: NTD thousand
(except EPS in NTD)

		April 1 to June 30, 2026		April 1 to June 30, 2025		January 1 to June 30, 2026		January 1 to June 30, 2025		
Item		Additional notes	Amount	%	Amount	%	Amount	%	Amount	%
Other comprehensive profit or loss (net)										
The items that are not re-classified as profit or loss										
8316	Unrealized valuation gains and losses on investment of equity instruments at fair value through other comprehensive income	6 (4)(20)	(\$ 3,908)	-	(\$ 2,232)	-	(\$ 21,710)	(1)	(\$ 5,470)	-
8320	The proportion of other comprehensive incomes from associates, and equity joint-ventures accounted for under the equity method – not reclassified as profit and loss	6 (20)	(1)	-	-	-	568	-	-	-
8310	Total amount of items not reclassified to profit or income		(3,909)	-	(2,232)	-	(21,142)	(1)	(5,470)	-
Items that may be re-classified subsequently under profit or loss										
8361	Exchange differences from the translation of financial statements of foreign operations	6 (20)	15,642	1	(127,946)	(6)	53,236	1	(101,955)	(2)
8370	The proportion of other comprehensive incomes from associates, and equity joint-ventures accounted for under the equity method – may be reclassified as profit and loss.	6 (20)	(15)	-	(498)	-	165	-	(453)	-
8399	Income tax related to items possibly be reclassified	6 (20)(27)	(3,129)	-	25,589	1	(10,647)	-	20,391	-
8360	Total amount of items probably reclassified to profit or loss subsequently		12,498	1	(102,855)	(5)	42,754	1	(82,017)	(2)
8300	Other comprehensive profit or loss (net)		<u>\$ 8,589</u>	<u>1</u>	<u>(\$ 105,087)</u>	<u>(5)</u>	<u>\$ 21,612</u>	<u>-</u>	<u>(\$ 87,487)</u>	<u>(2)</u>
8500	Current period other comprehensive income (Gross)		<u>\$ 190,344</u>	<u>10</u>	<u>(\$ 57,941)</u>	<u>(3)</u>	<u>\$ 396,356</u>	<u>9</u>	<u>\$ 77,874</u>	<u>2</u>
Net income (loss) attributable to:										
8610	Owners of parent		\$ 179,634	9	\$ 47,334	2	\$ 375,527	9	\$ 165,328	4
8620	Non-controlling interest		2,121	-	(188)	-	(783)	-	33	-
			<u>\$ 181,755</u>	<u>9</u>	<u>\$ 47,146</u>	<u>2</u>	<u>\$ 374,744</u>	<u>9</u>	<u>\$ 165,361</u>	<u>4</u>
Total comprehensive income attributable to:										
8710	Owners of parent		\$ 188,223	10	(\$ 57,753)	(3)	\$ 397,139	9	\$ 77,841	2
8720	Non-controlling interest		2,121	-	(188)	-	(783)	-	33	-
			<u>\$ 190,344</u>	<u>10</u>	<u>(\$ 57,941)</u>	<u>(3)</u>	<u>\$ 396,356</u>	<u>9</u>	<u>\$ 77,874</u>	<u>2</u>
Earnings per share										
9750	Basic earnings per share	6 (28)	\$ 1.44		\$ 0.38		\$ 3.02		\$ 1.31	
9850	Diluted earnings per share		\$ 1.44		\$ 0.38		\$ 3.01		\$ 1.31	

Please refer to the notes enclosed in the consolidated financial reports that are an integral part of the consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation
Representative: Wang Hsien, I-Chen

Manager: Wang, Hou-Kai

Accounting Supervisor: Hsiang, Hsien-Chieh

Cenra Inc. and subsidiaries
Consolidated statement of changes in equity
January 1 to June 30, 2026 and 2025

Unit: NTD thousand

		Equity of the parent company														Non-controlling interest	Total equity
		Capital surplus					Retained earnings			Other equity							
		Common stock capital	Capital surplus-issuance premium	Treasury stock trade	Others	Employee restricted stock	Legal reserve	Special reserve	Undistributed earnings	Exchange differences from the translation of financial statements of foreign operations	Unrealized gain or loss on assets at fair value through other comprehensive profit or loss	Unearned Employee Compensation	Treasury stock	Total			
Additional notes																	
<u>January 1 to June 30, 2025</u>																	
Balance at January 1		\$ 1,490,405	\$ 5,901,560	\$ 68,087	\$ 1,956	\$ -	\$ -	\$ 188,958	\$ 113,624	(\$ 85,170)	(\$ 137,597)	\$ -	(\$ 32,304)	\$ 7,509,519	\$ 39,832	\$ 7,549,351	
Net income		-	-	-	-	-	-	-	165,328	-	-	-	-	165,328	33	165,361	
Current period other comprehensive income	6 (4)(20)	-	-	-	-	-	-	-	-	(82,017)	(5,470)	-	-	(87,487)	-	(87,487)	
Current period other comprehensive income (loss)		-	-	-	-	-	-	-	165,328	(82,017)	(5,470)	-	-	77,841	33	77,874	
The 2024 appropriation and distribution of earnings 6 (19)																	
Legal reserve		-	-	-	-	-	11,362	-	(11,362)	-	-	-	-	-	-	-	
Special reserve		-	-	-	-	-	-	33,809	(33,809)	-	-	-	-	-	-	-	
Cash dividends		-	-	-	-	-	-	-	(59,571)	-	-	-	-	(59,571)	-	(59,571)	
Distribution of cash dividends from capital reserve	6 (18)	-	(89,356)	-	-	-	-	-	-	-	-	-	-	(89,356)	-	(89,356)	
Repurchase of treasury stock	6 (17)	-	-	-	-	-	-	-	-	-	-	-	(93,628)	(93,628)	-	(93,628)	
Equity instrument at fair value through other comprehensive income statement	6 (4)(20)	-	-	-	-	-	-	-	(61,981)	-	61,981	-	-	-	-	-	
Balance at June 30		\$ 1,490,405	\$ 5,812,204	\$ 68,087	\$ 1,956	\$ -	\$ 11,362	\$ 222,767	\$ 112,229	(\$ 167,187)	(\$ 81,086)	\$ -	(\$ 125,932)	\$ 7,344,805	\$ 39,865	\$ 7,384,670	
<u>January 1 to June 30, 2026</u>																	
Balance at January 1		\$ 1,497,656	\$ 5,812,204	\$ 68,389	\$ 9,562	\$ 17,692	\$ 11,362	\$ 222,767	\$ 252,494	(\$ 82,116)	(\$ 71,642)	(\$ 20,083)	(\$ 146,631)	\$ 7,571,654	\$ 39,978	\$ 7,611,632	
Net income		-	-	-	-	-	-	-	375,527	-	-	-	-	375,527	(783)	374,744	
Current period other comprehensive income	6 (4)(20)	-	-	-	-	-	-	-	-	42,754	(21,142)	-	-	21,612	-	21,612	
Current period other comprehensive income (loss)		-	-	-	-	-	-	-	375,527	42,754	(21,142)	-	-	397,139	(783)	396,356	
The 2025 appropriation and distribution of earnings 6 (19)																	
Legal reserve		-	-	-	-	-	24,361	-	(24,361)	-	-	-	-	-	-	-	
Cash dividends		-	-	-	-	-	-	-	(145,830)	-	-	-	-	(145,830)	-	(145,830)	
Repurchase of treasury stock	6 (17)	-	-	-	-	-	-	-	-	-	-	-	(15,671)	(15,671)	-	(15,671)	
Equity instrument at fair value through other comprehensive income statement	6 (4)(20)	-	-	-	-	-	-	-	(31,449)	-	31,449	-	-	-	-	-	
Difference between the actual acquisition or disposal of equity interest in a subsidiary and its book value	6 (18)(29)	-	-	-	(112)	-	-	-	(142,211)	-	-	-	-	(142,323)	(32,727)	(175,050)	
Cost of share-based remuneration	6 (16)(20)	-	-	-	-	-	-	-	-	-	-	6,026	-	6,026	-	6,026	
Balance at June 30		\$ 1,497,656	\$ 5,812,204	\$ 68,389	\$ 9,450	\$ 17,692	\$ 35,723	\$ 222,767	\$ 284,170	(\$ 39,362)	(\$ 61,335)	(\$ 14,057)	(\$ 162,302)	\$ 7,670,995	\$ 6,468	\$ 7,677,463	

Please refer to the notes enclosed in the consolidated financial reports that are an integral part of the consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation
Representative: Wang Hsien, I-Chen

Manager: Wang, Hou-Kai

Accounting Supervisor: Hsiang, Hsien-Chieh

Cenra Inc. and subsidiaries
Consolidated cash flow statement
January 1 to June 30, 2026 and 2025

Unit: NTD thousand

	<u>Additional notes</u>	<u>January 1 to June 30, 2026</u>	<u>January 1 to June 30, 2025</u>
<u>Cash flow from operating activities</u>			
Current year net profit before taxation		\$ 453,639	\$ 231,445
Adjustments			
Profits and loss			
Depreciation expenses	6 (24) (25)	174,770	168,509
Amortization expenses	6 (25)	5,502	5,323
Share-based payment	6 (16) (25)	6,026	-
Expected credit impairment (gain) loss	12 (2)	4,449	(22,534)
Decrease of allowance for sales return and allowance		(23,882)	(3,162)
Interest expenses	6 (26)	28,833	31,172
Interest income	6 (22)	(5,501)	(5,198)
Dividend income	6 (4)(23)	-	(2,280)
Shareholding in the affiliated companies and joint ventures under the equity method	6 (6)	(69,223)	7,321
Loss (gain) in disposal of real estate, plant buildings, equipment & facilities	6 (24)	11,052	(571)
Changes in assets/liabilities relating to operating activities			
Net changes in assets relating to operating activities			
Accounts receivable (including related party and non-related party)		96,416	(27,344)
Notes receivable (including related party and non-related party)		111,181	59,965
Finance lease receivables		321	-
Other account receivable (including related party and non-related party)		151,698	23,699
Inventory		(161,299)	213,993
Other current assets		(20,785)	(18,110)
Net changes in liabilities relating to operating activities			
Contractual liability- liquidity		2,692	1,383
Notes payable		(107)	(1,208)
Accounts payable		33,775	(179,487)
Other payables		(110,151)	(79,616)
Refund liability - liquidity		(24,964)	(25,526)
Other current liabilities- other		3,228	(1,034)
Other non-current liabilities		(1,345)	(382)
Cash inflow from operating activities		666,325	376,358
Interest received		4,281	3,839
Interest payment		(28,874)	(31,996)
Income tax payment		(58,972)	(62,391)
Income tax refund		-	4,497
Dividends received		33,221	54,722
Net cash inflow from operating activities		615,981	345,029

(Continued on next page)

Cenra Inc. and subsidiaries
Consolidated cash flow statement
January 1 to June 30, 2026 and 2025

Unit: NTD thousand

	<u>Additional notes</u>	<u>January 1 to June 30, 2026</u>	<u>January 1 to June 30, 2025</u>
<u>Cash flow from investing activities</u>			
Acquisition of financial assets at fair value through other comprehensive profit or loss		(\$ 66,060)	(\$ 97)
Disposal of financial assets at fair value through other comprehensive income	6 (4)	82,887	139,653
Acquisition of returned share capital from financial assets at fair value through other comprehensive income	6 (4)	7,442	-
Acquisition of investment under the equity method	7	-	(463)
Purchase of property, plant, and equipment	6 (30)	(91,170)	(76,974)
Proceeds from disposal of property, plant and equipment		5,168	681
Purchase of intangible assets		(3,110)	(116)
Increase of the financing amount receivable		(211,300)	(41,000)
Decrease (increase) in deposits paid		11,444	(7,795)
Decrease in other non-current assets		(842)	(1,425)
Net cash outflow (inflow) from investing activities		(265,541)	12,464
<u>Cash flow from financing activities</u>			
Increase in Shot-term borrowings	6 (31)	19,458	497,762
Increase (decrease) in short-term payable notes	6 (31)	(350,000)	288,008
Lease principal repayment	6 (31)	(28,544)	(24,414)
Current borrowing amount of long-term loan	6 (31)	100,000	140,000
Current repaying amount of long-term loan	6 (31)	(10,400)	(1,032,600)
Payable of lease liabilities	6 (31)	(1,783)	(2,396)
Consideration paid for transactions with non-controlling interests	6 (29) and 7	(175,050)	-
Repurchase of treasury stock	6 (17)	(15,671)	(93,628)
Net cash outflow from financing activities		(461,990)	(227,268)
Impact of changes in exchange rate on cash and cash equivalents		41,809	(34,172)
Decrease (increase) in cash and cash equivalents for the current period		(69,741)	96,053
Balance of cash and cash equivalents, beginning of period		729,497	588,011
Balance of cash and cash equivalent, end of period		<u>\$ 659,756</u>	<u>\$ 684,064</u>

Please refer to the notes enclosed in the consolidated financial reports that are an integral part of the consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation Manager: Wang, Hou-Kai Accounting Supervisor: Hiang, Hsien-Chieh
Representative: Wang Hsien, I-Chen

Cenra Inc. and subsidiaries
Notes to consolidated financial statement
Q2 2026 and 2025

Unit: NTD thousand
(Except where otherwise stated)

1. Company history

- (1) The Company was established on September 2, 2024, listed on the TWSE on the same day, and renamed Cenra Inc. on July 9, 2025.
- (2) On May 28, 2024, China Chemical & Pharmaceutical Co., Ltd. (hereinafter referred to as “CCPC”) resolved to apply for the establishment of the Company at the shareholders’ meeting and the meeting of the Company’s founders. The Company acquired 100% of the equity of CCPC through a share swap. The consideration for the share swap was 0.5 shares of the Company for every 1 share of CCPC. The Company completed the share swap transaction on September 2, 2024. CCPC became a wholly owned subsidiary of the Company and ceased its listing and public offering. The Company’s common stock shares are listed on the Taiwan Stock Exchange (TWSE) on the same day with the stock code of “3716.”
- (3) The Company and its subsidiary (hereinafter referred to as “the Group”) have major business in manufacturing and selling pharmaceutical products and health products, as well as the import business of related medical appliances.

2. Financial statements approval date and procedure

These consolidated financial statements were authorized by the Board of Directors on August 6, 2026.

3. Application of New Standards, Amendments and Interpretations

- (1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS”) as endorsed and issued into effect by the Financial Supervisory Commission (“FSC”)

The new publication, amendments, and revision of the 2026 International Financial Reporting Standards (IFRS) that was endorsed and issued into effect by the Financial Supervisory Commission are as follows:

New releases / amendments / revisions of the Standards and Interpretations	The effective date announced by the International Accounting Standards Board
Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”	January 1, 2026
Amendments to IFRS 9 and IFRS 7, “Contracts Referencing Nature-dependent Electricity”	January 1, 2026
IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17 - Application of IFRS 17 and IFRS 9 — Comparative Information	January 1, 2023
Annual Improvements to IFRSs—Volume 11	January 1, 2026

The above standards and interpretations have no significant impact to the Group’s financial

position and financial performance based on the Group's assessment.

(2) Effect of new issuances of or amendments to IFRS as endorsed by the FSC but not yet adopted by the Company and subsidiaries

The new publication, amendments, and revision of the 2027 International Financial Reporting Standards (IFRS) that was recognized by the FSC follows:

New releases / amendments / revisions of the Standards and Interpretations	The effective date announced by the International Accounting Standards Board
IFRS 18 "Presentation and Disclosure in Financial Statements"	January 1, 2027 (Note 1)
IFRS 19 "Subsidiaries without Public Accountability: Disclosures"	January 1, 2027
Amendments to IAS 21 "Translation to a Hyperinflationary Presentation Currency"	January 1, 2027
Amendments to IAS 28 "Amendments to the Fair Value Option for Investments in Associates and Joint Ventures"	January 1, 2027 (Note 2)

Note 1: An entity shall apply IFRS 18, "Presentation and Disclosure in Financial Statements," for annual reporting periods beginning on or after January 1, 2028, and may elect to apply it earlier.

Note 2: An entity shall apply these amendments at the same time as it applies IFRS 18.

Except for the following statements, the Group has assessed the aforementioned standards, interpretations, and interpretative announcements and has concluded that they have no material impact on the Group's financial position and financial performance:

IFRS 18 "Presentation and Disclosure in Financial Statements"

IFRS 18 "Presentation and Disclosure in Financial Statements" has replaced IAS 1, updating the structure of the statement of comprehensive income, and adding the disclosure of management performance measurements, while strengthening the summary and division of the use in the main financial statements and notes.

(3) IFRS issued by IASB but not yet endorsed by the FSC

The newly released, revised and amended IFRS standards and interpretations by the IASB but not yet recognized by the FSC are summarized as follows:

New releases / amendments / revisions of the Standards and Interpretations	The effective date announced by the International Accounting Standards Board
Amendment to IFRS 10 and IAS 28 "The Assets Sales or Purchase between Investors and Their Affiliates or Joint Ventures"	To be determined by the "International Accounting Standards Board (IASB)."
IFRS 20 "Regulatory Assets and Regulatory Liabilities"	January 1, 2029

The Group has assessed the aforementioned standards, interpretations, and interpretative announcements and has concluded that they have no material impact on the Group's financial position and financial performance.

4. Summary of significant accounting policies

The significant accounting policies, except for the statement of compliance, the basis of preparation, the basis of consolidation, and the new parts are as follows, which are the same as Note 4 to the consolidated financial statements of 2025. These policies have been consistently applied to all the period presented, unless otherwise stated.

(1) Compliance Statement

1. These consolidated financial statements are prepared in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” and the International Accounting Standards and IAS 34 “Interim Financial Reporting”.
2. The consolidated financial statements shall be read together with the 2025 consolidated financial statements.

(2) Basis of preparation

1. Except for the following items, these consolidated statements have been prepared under the historical cost convention:
 - (1) Financial assets measured at fair value through profit or loss (including derivatives).
 - (2) Financial assets at fair value through other comprehensive income
 - (3) Defined benefit assets and liabilities recognized at the net amount of pension fund assets less the present value of defined benefit obligations.
2. The financial statements prepared in accordance with the International Financial Reporting Standards, international accounting standards, interpretation and interpretation notice (referred to as “IFRS” hereinafter) that is endorsed and issued into effect by the FSC requires the use of some critical accounting estimates; also, the judgment by the management is required while using the Group’s accounting policies. Please refer to Note 5 for the items involving extensive judgment or complexity, or significant assumptions and estimates related to the consolidated financial statements.

(3) Basis of consolidation

1. The basis of preparation for consolidated financial statements

The preparation principles of the consolidated financial statements are the same as those of the 2025 consolidated financial statements.

2. Subsidiaries included in the financial statements:

Investor	Name of the subsidiary	Nature of the operation	Percentage of shareholdings (%)			Remarks
			June 30, 2026	December 31, 2025	June 30, 2025	
Cenra Inc.	China Chemical & Pharmaceutical Co., Ltd. (CCPC)	Manufacture and sales of Western medicine preparations and health-care articles.	100.00	100.00	100.00	
Cenra Inc.	Chunghwa Yuming Healthcare Co., Ltd. (Chunghwa Yuming)	Wholesale of medicine and medical equipment	100.00	100.00	100.00	Note 3
Cenra Inc.	Providence Investments Inc.	General investment businesses	100.00	100.00	100.00	Note 2
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Senior Lifestyle Services Co. Ltd. (Chunghwa Senior Lifestyle Services)	Medicine, wholesale of medicine equipment and home care service	100.00	100.00	100.00	
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Holding Co., Ltd. (Chunghwa)	Professional investment company	100.00	100.00	100.00	
China Chemical & Pharmaceutical Co., Ltd.	Tairung Enterprise Co., Ltd. (Tairung)	Manufacture and sales of glass, plastics made containers	99.96	71.64	71.64	Note 4
Chunghwa Yuming	Chunghwa Biomedical	Manufacturer of	75.23	75.23	75.23	

Investor	Name of the subsidiary	Nature of the operation	Percentage of shareholdings (%)			Remarks
			June 30, 2026	December 31, 2025	June 30, 2025	
Healthcare Co., Ltd.	Technology Corp.	cleaning products				
Chunghwa Holding Co., Ltd	Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd. (SCCPC)	Manufacture and sales of pharmaceutical medicine and health products.	100.00	100.00	100.00	
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd.	Wholesale and sales of pharmaceutical medicine and medical equipment.	100.00	100.00	100.00	
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Shanghai Yuhou Trading Co., Ltd. (formerly known as Pei Fu (Shanghai) Co., Ltd.)	Wholesale and sales of medical equipment.	100.00	100.00	100.00	
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Suzhou Chung-Hwa Le Huo Jian Kang Co., Ltd.	E-commerce sales of health products	100.00	100.00	100.00	
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Chung-Hwa Le Huo Jian Kang (HK) Co., Ltd.	Biotech products sold as an agent	100.00	100.00	100.00	Note 1

Note 1: Chung-Hwa Le Huo Jian Kang (HK) Co., Ltd. not yet invested capital as of June 30, 2026.

Note 2: Providence Investments was established on June 5, 2025

Note 3: On June 30, 2025, CCPC was reorganized and restructured, with Cenra holding 100% shares held of Chunghwa Yuming Healthcare.

Note 4: On May 18, 2026, China Chemical & Pharmaceutical Co., Ltd. purchased a 28.32% equity interest in Tai Jung from Magitech Enterprise Co., Ltd., an entity controlled by key management personnel, for cash consideration of NTD 175,050. Together with its originally held equity interest, China Chemical & Pharmaceutical Co., Ltd. held a total equity interest of 99.96% in Tai Jung.

3. Subsidiary company not included in the consolidated financial statements are as follows: Not applicable.
4. Adjustments on subsidiary companies with different accounting periods: Not applicable.
5. Significant limitations: Not applicable.
6. Subsidiaries over which the Group has significant influence but not control: none

(4) Employee benefits

Pension - defined benefit plan

The interim pension cost is calculated based on the actuarial pension cost rate on the last day of the previous fiscal year from the beginning of the year to the end of the period. If there is a significant market change, significant reduction, settlement, or other significant one-time event after the end date, it is adjusted and the relevant information is correspondingly disclosed.

(5) Income tax

The average effective tax rate used to estimate the interim income tax expense shall be applicable to the interim income before tax, and the relevant information is correspondingly disclosed.

5. Critical accounting judgments, estimates and key sources of assumption uncertainty

There is no significant change in the current period. Please refer to Note 5 to the 2025 consolidated financial statements.

6. Summary of significant accounting titles

(1) Cash and cash equivalents

	June 30, 2026	December 31, 2025	June 30, 2025
Cash on hand	\$ 3,814	\$ 4,046	\$ 4,173
Check deposit and demand deposit	608,818	680,541	633,059
Cash equivalents- time deposits	46,890	44,910	46,832
Cash equivalents- banker's acceptance bill	234	-	-
	<u>\$ 659,756</u>	<u>\$ 729,497</u>	<u>\$ 684,064</u>

1. The financial institutions that the Group deals with are with good credit quality; also, the Group deals with a number of financial institutions to diversify credit risk; therefore, the possibility of default is very unlikely.

2. None of the Group's cash and cash equivalents pledged to others as collateral.

(2) Note receivable and accounts receivable

	June 30, 2026	December 31, 2025	June 30, 2025
Notes receivable	\$ 245,502	\$ 334,422	\$ 392,664
Less: Allowance for losses	(221)	(436)	(815)
	<u>\$ 245,281</u>	<u>\$ 333,986</u>	<u>\$ 391,849</u>
Accounts receivable	\$ 1,541,700	\$ 1,622,252	\$ 1,613,800
Less: Allowance for sales and discount	(120,730)	(144,612)	(133,199)
Less: Allowance for losses	(10,630)	(11,315)	(9,171)
	<u>\$ 1,410,340</u>	<u>\$ 1,466,325</u>	<u>\$ 1,471,430</u>

1. The aging analysis of accounts receivable and bill receivable is as follows:

	June 30, 2026		December 31, 2025	
	Accounts receivable	Notes receivable	Accounts receivable	Notes receivable
Not-overdue	\$ 1,487,997	\$ 243,885	\$ 1,573,177	\$ 333,642
Overdue within 1-90 days	46,110	1,617	41,548	780
Overdue within 91-180 days	4,510	-	4,320	-
Overdue exceeding 181 days	3,083	-	3,207	-
	<u>\$ 1,541,700</u>	<u>\$ 245,502</u>	<u>\$ 1,622,252</u>	<u>\$ 334,422</u>

	June 30, 2025	
	Accounts receivable	Notes receivable
Not-overdue	\$ 1,581,752	\$ 392,182
Overdue within 1-90 days	21,372	482
Overdue within 91-180 days	7,868	-
Overdue exceeding 181 days	2,808	-
	<u>\$ 1,613,800</u>	<u>\$ 392,664</u>

The aforementioned aging analysis is based on the overdue days.

2. Account and note receivables as of June 30, 2026, December 31 and June 30, 2025 were from customer contracts. Account receivables (including note receivables) and the associated allowed made stood at NTD 1,795,434 and NTD 12,153, respectively, on January 1, 2025.
3. The exposure amounts of the maximum credit risk which can represent the accounts receivable and bill receivable of the Group without considering the possessed collateral or other credit enhancement condition on June 30, 2026, December 31 and June 30, 2025 are its book amount.
4. The accounts receivable listed in the account of the Group does not possess any collateral.
5. Please find Note 12 (2) for the relevant explanation about credit risk.

(3) Inventory

	June 30, 2026		
	Cost	Allowance for loss from price declination	Book value
Raw materials	\$ 1,156,399	(\$ 12,123)	\$ 1,144,276
Material	214,158	(1,630)	212,528
Work in process	380,227	(2,383)	377,844
Finished products	606,274	(18,427)	587,847
Merchandise inventory	594,960	(33,792)	561,168
	<u>\$ 2,952,018</u>	<u>(\$ 68,355)</u>	<u>\$ 2,883,663</u>
	December 31, 2025		
	Cost	Allowance for loss from price declination	Book value
Raw materials	\$ 985,945	(\$ 11,338)	\$ 974,607
Material	187,178	(1,544)	185,634
Work in process	344,239	(1,167)	343,072
Finished products	611,979	(19,178)	592,801
Merchandise inventory	649,198	(36,653)	612,545
	<u>\$ 2,778,539</u>	<u>(\$ 69,880)</u>	<u>\$ 2,708,659</u>

	June 30, 2025		
	Cost	Allowance for loss from price declination	Book value
Raw materials	\$ 958,247	(\$ 14,467)	\$ 943,780
Material	180,108	(2,835)	177,273
Work in process	344,474	(402)	344,072
Finished products	586,068	(29,047)	557,021
Merchandise inventory	634,089	(25,843)	608,246
	<u>\$ 2,702,986</u>	<u>(\$ 72,594)</u>	<u>\$ 2,630,392</u>

The cost of inventory recognized as expense of the Group within the current period:

	April 1 to June 30, 2026	April 1 to June 30, 2025
Cost of inventory sold	\$ 1,172,821	\$ 1,279,829
Labor service cost	31,974	29,378
Gain from inventory price recovery	(7,138)	(7,656)
Inventory disposition losses	20,399	2,853
	<u>\$ 1,218,056</u>	<u>\$ 1,304,404</u>
	January 1 to June 30, 2026	January 1 to June 30, 2025
Cost of inventory sold	\$ 2,457,208	\$ 2,610,765
Labor service cost	63,242	57,227
Gain from inventory price recovery	(907)	(11,770)
Inventory disposition losses	21,150	4,302
	<u>\$ 2,540,693</u>	<u>\$ 2,660,524</u>

For the three months ended June 30, 2026 and 2025 and the six months ended June 30, 2026 and 2025, as the market prices of some of the Group's inventory recovered and the inventories that had been recognized in depreciation losses in prior years were scrapped, it was recognized in gain from price recovery.

(4) Financial assets at fair value through other comprehensive profit or loss

<u>Item</u>	<u>June 30, 2026</u>	<u>December 31, 2025</u>	<u>June 30, 2025</u>
Non-current items:			
Equity instruments			
Listed stocks	\$ 36,907	\$ 63,792	\$ 122,350
Non-listed shares, OTC, emerging stocks	82,543	102,704	59,069
	<u>\$ 119,450</u>	<u>\$ 166,496</u>	<u>\$ 181,419</u>

1. The Group decides to classify the stock of strategic as investment financial assets at fair value through other comprehensive income.
2. For the six months ended June 30, 2026, capital reduction and refund of the Group's investment in financial assets measured at fair value through other comprehensive income amounted to NTD 7,442.
3. For the three months ended June 30, 2026 and 2025 and the six months ended June 30, 2026 and 2025, the Group sold equity investments with fair values of NTD 80,786, NTD 0, NTD 82,887 and NTD 139,653, respectively; transferred NTD 28,600, NTD 0, NTD 31,449 and NTD 61,981, respectively, from other equity to retained earnings; and the cumulative disposal losses on these investments were NTD (28,600), NTD 0, NTD (31,449) and NTD (61,981), respectively.
4. The details of financial assets at fair value through other comprehensive income which recognized in income and comprehensive income are as follows:

<u>Item</u>	<u>April 1 to June 30, 2026</u>	<u>April 1 to June 30, 2025</u>
<u>Equity measured at fair value through other comprehensive income</u>		
Recognized in comprehensive income of changes in fair value		
The party still in possession at the end of this term	(\$ 4,477)	(\$ 2,232)
The accumulated losses change to retained earnings (post-tax profit or loss)		
Due to the reclassification of removed items	(\$ 28,600)	\$ -
Recognized as dividend in income in profit		
The party still in possession at the end of this term	\$ -	\$ 2,280
<u>Item</u>	<u>January 1 to June 30, 2026</u>	<u>January 1 to June 30, 2025</u>
<u>Equity measured at fair value through other comprehensive income</u>		
Recognized in comprehensive income of changes in fair value		
The party still in possession at the end of this term	(\$ 21,710)	\$ 5,470
The accumulated losses change to retained earnings (post-tax profit or loss)		
Due to the reclassification of removed items	(\$ 31,449)	(\$ 61,981)
Recognized as dividend in income in profit		
The party still in possession at the end of this term	\$ -	\$ 2,280

(5) Financial assets measured at the amortized cost

<u>Item</u>	<u>June 30, 2026</u>	<u>December 31, 2025</u>	<u>June 30, 2025</u>
Current items:			
Time deposits	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 88,414</u>
Non-current items:			
Time deposits	<u>\$ 141,913</u>	<u>\$ 134,866</u>	<u>\$ -</u>

1. Financial assets measured on the basis of amortized cost is recognized as income and specified as follows:

	<u>April 1 to June 30, 2026</u>	<u>April 1 to June 30, 2025</u>
Interest income	<u>\$ 615</u>	<u>\$ 660</u>
	<u>January 1 to June 30, 2026</u>	<u>January 1 to June 30, 2025</u>
Interest income	<u>\$ 1,220</u>	<u>\$ 1,359</u>

2. In the absence of collateral or other credit enhancement, the maximum amount of credit risk exposure of the symbolic financial assets measured on the basis of amortized cost held by the Group was NTD 141,913, NTD 134,866 and NTD 88,414, respectively as of June 30, 2026, December 31 and June 30, 2025.
3. The Group did not pledge any financial assets measured on the basis of amortized cost under lien.
4. For additional information on the financial assets measured on the basis of amortized cost, refer to Note 12, (2). The Group invests the certificates of deposits only with financial institutions in good credit standing. Default is unlikely to occur.

(6) Investment under the equity method

<u>Name of investee</u>	<u>June 30, 2026</u>	<u>December 31, 2025</u>	<u>June 30, 2025</u>
Affiliated enterprises:			
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB)	\$ 926,769	\$ 903,990	\$ 962,543
Sino-Japan Chemical Co., Ltd. (Sino-Japan Chemical)	530,905	516,506	486,162
PHERMPEP CO., LTD. (PHERMPEP)	6,007	6,442	2,093
Wuxi Jirui Medical Technology Co., Ltd. (Wuxi Jirui)	1,988	1,911	1,891
	<u>\$ 1,465,669</u>	<u>\$ 1,428,849</u>	<u>\$ 1,452,689</u>

1. Affiliated enterprises

- (1) Basic information of significant associate of the Group is as follows:

Company name	Major places of business	Ratio of Shareholding		Nature of relationship	Measuring method
		June 30, 2026	December 31, 2025		
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	Taiwan	28.05%	28.05%	Suppliers	Equity method
SINO-JAPAN CHEMICAL., CO., LTD	Taiwan	21.99%	21.99%	Financial investment	Equity method

Company name	Major places of business	Ratio of Shareholding		Nature of relationship	Measuring method
			June 30, 2025		
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	Taiwan		28.05%	Suppliers	Equity method
SINO-JAPAN CHEMICAL., CO., LTD	Taiwan		21.99%	Financial investment	Equity method

(2) Financial information of the Group's major associates is summarized as follows:

Balance Sheet

Chunghwa Chemical Synthesis & Biotech Co., Ltd.			
	June 30, 2026	December 31, 2025	June 30, 2025
Current assets	\$ 1,154,376	\$ 1,058,883	\$ 1,295,166
Non-Current assets	3,204,919	3,258,470	3,297,496
Current liabilities	(284,140)	(356,706)	(460,021)
Non-current liabilities	(872,063)	(873,307)	(874,360)
Total net assets	<u>\$ 3,203,092</u>	<u>\$ 3,087,340</u>	<u>\$ 3,258,281</u>
Book value of the associate	<u>\$ 926,769</u>	<u>\$ 903,990</u>	<u>\$ 962,543</u>

SINO-JAPAN CHEMICAL., CO., LTD			
	June 30, 2026	December 31, 2025	June 30, 2025
Current assets	\$ 2,306,049	\$ 2,292,150	\$ 2,124,603
Non-Current assets	634,042	615,861	621,080
Current liabilities	(358,417)	(407,183)	(348,287)
Non-current liabilities	(79,867)	(64,511)	(99,098)
Total net assets	<u>\$ 2,501,807</u>	<u>\$ 2,436,317</u>	<u>\$ 2,298,298</u>
Book value of the associate	<u>\$ 530,905</u>	<u>\$ 516,506</u>	<u>\$ 486,162</u>

Comprehensive income statement

Chunghwa Chemical Synthesis & Biotech Co., Ltd.

	April 1 to June 30, 2026	April 1 to June 30, 2025
Income	<u>\$ 305,180</u>	<u>\$ 344,039</u>
Current year profit of continuing business units	\$ 41,527	(\$ 67,332)
Other comprehensive income (post-tax profit or loss)	<u>1,162</u>	<u>(16,760)</u>
Current period other comprehensive income (Gross)	<u>\$ 42,689</u>	<u>(\$ 84,092)</u>

	Chunghwa Chemical Synthesis & Biotech Co., Ltd.	
	January 1 to June 30, 2026	January 1 to June 30, 2025
Income	<u>\$ 666,405</u>	<u>\$ 536,991</u>
Current year profit of continuing business units	\$ 132,128	(\$ 60,014)
Other comprehensive income (post-tax profit or loss)	<u>3,337</u>	<u>(5,384)</u>
Current period other comprehensive income (Gross)	<u>\$ 135,465</u>	<u>(\$ 65,398)</u>

	SINO-JAPAN CHEMICAL., CO., LTD	
	April 1 to June 30, 2026	April 1 to June 30, 2025
Income	<u>\$ 717,828</u>	<u>\$ 653,512</u>
Current year profit of continuing business units	\$ 127,006	\$ 45,561
Current period other comprehensive income (Gross)	<u>\$ 127,006</u>	<u>\$ 45,561</u>
Dividends received from affiliated subsidiaries	<u>\$ 33,221</u>	<u>\$ 54,722</u>

	SINO-JAPAN CHEMICAL., CO., LTD	
	January 1 to June 30, 2026	January 1 to June 30, 2025
Income	<u>\$ 1,441,186</u>	<u>\$ 1,270,844</u>
Current year profit of continuing business units	\$ 216,588	\$ 96,792
Current period other comprehensive income (Gross)	<u>\$ 216,588</u>	<u>\$ 96,792</u>
Dividends received from affiliated subsidiaries	<u>\$ 33,221</u>	<u>\$ 54,722</u>

- (3) The share of the operating results of individual insignificant associates of the Group is summarized as follows:

	April 1 to June 30, 2026	April 1 to June 30, 2025
Net loss of current period	(\$ 794)	(\$ 2,818)
	January 1 to June 30, 2026	January 1 to June 30, 2025
Net loss of current period	(\$ 963)	(\$ 4,124)

(4) The shares of profit and/or loss at equity method over the associates as follows:

Name of affiliated enterprise	April 1 to June 30, 2026	April 1 to June 30, 2025
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	\$ 4,405	(\$ 21,451)
SINO-JAPAN CHEMICAL CO., LTD	27,924	10,017
PHERMPEP CO., LTD.	(788)	(563)
Wuxi Jirui Medical Technology Co., Ltd.	(6)	(2,255)
	<u>\$ 31,535</u>	<u>(\$ 14,252)</u>

Name of affiliated enterprise	January 1 to June 30, 2026	January 1 to June 30, 2025
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	\$ 22,566	(\$ 24,478)
SINO-JAPAN CHEMICAL CO., LTD	47,620	21,281
PHERMPEP CO., LTD.	(955)	(1,867)
Wuxi Jirui Medical Technology Co., Ltd.	(8)	(2,257)
	<u>\$ 69,223</u>	<u>(\$ 7,321)</u>

- (5) The significant associate of the Group-CCSB is public offering and its fair values of June 30, 2026, December 31 and June 30, 2025 are, respectively, NTD 754,048, NTD 720,607 and NTD 781,017.
- (6) The company holds 28.05% equity of Chunghwa Chemical Synthesis Biotech Co., Ltd. (CCSB) and is the largest shareholder of CCSB. Considering the participation of other shareholders in the previous shareholders meeting of CCSB and the record of voting rights casted on major proposals, it indicates that the Group is incapable of leading relevant activities. Therefore, it has no control over CCSB, but a significant influence.

(7) Property, plant, and equipment

2026							
	Land	Buildings and structures	Machinery equipment	Transport equipment	Uncompleted construction and equipment pending inspection	Others	Total
January 1							
Cost	\$ 1,021,812	\$ 3,529,191	\$ 1,698,379	\$ 41,557	\$ 78,017	\$ 1,412,228	\$ 7,781,184
Accumulated depreciation	-	(1,766,784)	(1,055,360)	(32,329)	-	(974,188)	(3,828,661)
	<u>\$ 1,021,812</u>	<u>\$ 1,762,407</u>	<u>\$ 643,019</u>	<u>\$ 9,228</u>	<u>\$ 78,017</u>	<u>\$ 438,040</u>	<u>\$ 3,952,523</u>
January 1	\$ 1,021,812	\$ 1,762,407	\$ 643,019	\$ 9,228	\$ 78,017	\$ 438,040	\$ 3,952,523
Additions	-	9,746	10,960	1,460	55,615	14,159	91,940
Transfer	-	3,497	28,032	-	(42,461)	10,932	-
Disposition	-	-	(11,456)	(201)	-	(4,563)	(16,220)
Depreciation expenses	-	(53,333)	(42,150)	(1,822)	-	(45,514)	(142,819)
Net exchange differences	-	3,549	3,598	85	454	2,390	10,076
June 30	<u>\$ 1,021,812</u>	<u>\$ 1,725,866</u>	<u>\$ 632,003</u>	<u>\$ 8,750</u>	<u>\$ 91,625</u>	<u>\$ 415,444</u>	<u>\$ 3,895,500</u>
June 30							
Cost	\$ 1,021,812	\$ 3,548,529	\$ 1,711,581	\$ 42,959	\$ 91,625	\$ 1,392,146	\$ 7,808,652
Accumulated depreciation	-	(1,822,663)	(1,079,578)	(34,209)	-	(976,702)	(3,913,152)
	<u>\$ 1,021,812</u>	<u>\$ 1,725,866</u>	<u>\$ 632,003</u>	<u>\$ 8,750</u>	<u>\$ 91,625</u>	<u>\$ 415,444</u>	<u>\$ 3,895,500</u>

2025

	Land	Buildings and structures	Machinery equipment	Transport equipment	Uncompleted construction and equipment pending inspection	Others	Total
January 1 Cost	\$ 1,021,812	\$ 3,577,674	\$ 1,610,150	\$ 41,681	\$ 113,032	\$ 1,372,199	\$ 7,736,548
Accumulated depreciation	-	(1,727,106)	(988,606)	(33,458)	-	(910,063)	(3,659,233)
	<u>\$ 1,021,812</u>	<u>\$ 1,850,568</u>	<u>\$ 621,544</u>	<u>\$ 8,223</u>	<u>\$ 113,032</u>	<u>\$ 462,136</u>	<u>\$ 4,077,315</u>
January 1 Additions	\$ 1,021,812	\$ 1,850,568	\$ 621,544	\$ 8,223	\$ 113,032	\$ 462,136	\$ 4,077,315
Transfer	-	6,152	26,791	1,219	25,558	12,439	72,159
Disposition	-	2,186	36,538	20	(52,767)	14,023	-
Depreciation expenses	-	-	-	(87)	-	(23)	(110)
Net exchange differences	-	(52,223)	(40,554)	(1,421)	-	(45,141)	(139,339)
June 30	<u>-</u>	<u>(7,888)</u>	<u>(7,214)</u>	<u>(221)</u>	<u>(889)</u>	<u>(4,813)</u>	<u>(21,025)</u>
	<u>\$ 1,021,812</u>	<u>\$ 1,798,795</u>	<u>\$ 637,105</u>	<u>\$ 7,733</u>	<u>\$ 84,934</u>	<u>\$ 438,621</u>	<u>\$ 3,989,000</u>
June 30 Cost	\$ 1,021,812	\$ 3,574,146	\$ 1,640,346	\$ 41,137	\$ 84,934	\$ 1,372,623	\$ 7,734,998
Accumulated depreciation	-	(1,775,351)	(1,003,241)	(33,404)	-	(934,002)	(3,745,998)
	<u>\$ 1,021,812</u>	<u>\$ 1,798,795</u>	<u>\$ 637,105</u>	<u>\$ 7,733</u>	<u>\$ 84,934</u>	<u>\$ 438,621</u>	<u>\$ 3,989,000</u>

- Notes: 1. Please refer to Note 8 for the information on the property, plant, and equipment provided as collateral.
2. When the Group obtains government subsidies for property, plant and equipment, it is debited to the carrying amount and recognized in profit or loss through a decrease in depreciation expenses over the useful life of the asset.
3. The Group rented the land of No. 23, Xiangyang Rd., Taipei City from Jen-Chi Relief Institution, the lease term is from January 1, 2025 to December 31, 2029 with the rental of NTD 322 paid by the month. According to contractual requirement, if the contract is not renewed at expiration, the construction on the lease land shall unconditionally be torn down and the land should be returned. As of June 30 2026, the remaining balance of depreciation of the construction amounted to NTD 43,840.

(8) Lease transaction - lessee

- Underlying assets leased by the Group include land lots, buildings, machinery and equipment, business vehicles, and office equipment, with lease terms generally ranging from one to fifty years. Lease agreements were negotiated individually with various terms and conditions. There are specific no restrictions specified, except that the leased assets cannot be used as loan guarantee.
- Carrying amount and recognized amortization for right-of-use assets are as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
	Book value	Book value	Book value
Land	\$ 47,569	\$ 47,128	\$ 47,600
Buildings	253,500	261,721	285,889
Machinery equipment	38,899	39,327	37,700
Delivery facilities (business vehicles)	6,039	5,795	7,784
Furniture and fixtures	13,472	15,151	-
	<u>\$ 359,479</u>	<u>\$ 369,122</u>	<u>\$ 378,973</u>

	April 1 to June 30, 2026	April 1 to June 30, 2025
	Depreciation expenses	Depreciation expenses
Land	\$ 1,017	\$ 967
Buildings	11,529	10,857
Machinery equipment	1,070	982
Delivery facilities (business vehicles)	1,198	1,049
Furniture and fixtures	840	-
	<u>\$ 15,654</u>	<u>\$ 13,855</u>

	January 1 to June 30, 2026	January 1 to June 30, 2025
	Depreciation expenses	Depreciation expenses
Land	\$ 2,019	\$ 1,940
Buildings	22,250	21,470
Machinery equipment	2,123	2,021
Delivery facilities (business vehicles)	2,192	2,099
Furniture and fixtures	1,679	-
	<u>\$ 30,263</u>	<u>\$ 27,530</u>

- The Group's right-of-use assets for the six months ended June 30, 2026 and 2025 increased by NTD 18,082 and NTD 46,329 respectively.
- Profit and loss items relating to lease contracts:

	April 1 to June 30, 2026	April 1 to June 30, 2025
<u>Profit and loss items with current impacts</u>		
Interest expense on the lease liability	\$ 1,723	\$ 1,801
Low-value leases expense	696	622
Short-term lease expense	10,621	4,648

	January 1 to June 30, 2026	January 1 to June 30, 2025
<u>Profit and loss items with current impacts</u>		
Interest expense on the lease liability	\$ 3,455	\$ 3,512
Low-value leases expense	1,281	1,101
Short-term lease expense	17,556	8,513

5. The Group's total lease cash outflows for the six months ended June 30, 2026 and 2025 were NTD 50,836 and NTD 37,540, respectively.

6. Options to extend lease

- (1) Options to extend lease term are included in land leases for office buildings, which have helped increase operation agility for the Group.
- (2) Upon determining lease term, the Group has factored in all facts and condition that would produce future economy incentives. Lease term will be reassessed in the case of significant events when the decision of whether to exercise the extension option or not exercise the termination option is affected.
- (3) Given the assessment of exercising an option to extend the lease, the right-of-use assets and lease liabilities increased by NTD 0, NTD 16,492 and NTD 16,492 in June 30, 2026, December 31, and June 30, 2025, respectively.

7. Sub-subsidiary, Suzhou Chung-Hua Chemical & Pharmaceutical has received a subsidy of NTD 110,460 (or CNY 22,950 thousand) from the local government industrial funding, which was to reduce the cost of the rights to use land (recorded as long-term prepaid rent). The subsidy was then transferred to "right-of-use asset" in 2019 and will be recognized as depreciation expenses under profit and loss throughout the lease term.

8. As the Group has leased some buildings and is contractually obligated to dismantle, remove, or restore the location(s), the present value of the costs expected to be incurred in dismantling, removing, or restoring the location(s) was recognized in decommissioning liabilities as of June 30, 2026, December 31, and June 30, 2025. The decommissioning liabilities recognized by the Group totaled NTD 4,705, NTD 4,671 and NTD 4,637 (recognized in other non-current liabilities), and the amortized interest expense for the three months ended June 30, 2026 and 2025 and six months ended June 30, 2026 and 2025 were NTD 17, NTD 16, NTD 34 and NTD 33, respectively.

(9) Lease transaction - lessor

1. Underlying assets leased out by the Group include buildings, with lease terms generally of six years. The lease agreements were negotiated individually with various terms and conditions.

2. The Group leases out buildings under finance leases. According to the clauses of the lease agreements, the lease term covers the majority of the underlying assets' economic lives. Profit and loss items relating to lease contracts:

	April 1 to June 30, 2026	April 1 to June 30, 2025
Finance income from net investment in leases	<u>\$ 24</u>	<u>\$ -</u>
	January 1 to June 30, 2026	January 1 to June 30, 2025
Finance income from net investment in leases	<u>\$ 50</u>	<u>\$ -</u>

3. The maturity analysis of undiscounted lease payments leased by the Group under finance leases is as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Current year	\$ 370	\$ -	\$ -
Over the next year	743	742	-
Over the next two years	743	743	-
Over the next three years	743	743	-
Over the next four years	743	743	-
Over the next five years	743	743	-
Over the next six years	-	743	-
Total	<u>\$ 4,085</u>	<u>\$ 4,457</u>	<u>\$ -</u>

4. The information on the reconciliation of undiscounted lease payments leased by the Group under finance leases and the net investment in leases is as follows:

	June 30, 2026		December 31, 2025		June 30, 2025	
	Current	Non-Current	Current	Non-Current	Current	Non-Current
Undiscounted lease payments	\$ 743	\$ 3,342	\$ 743	\$ 3,714	\$ -	\$ -
Unearned finance income	(88)	(180)	(96)	(222)	-	-
Net investment in leases	<u>\$ 655</u>	<u>\$ 3,162</u>	<u>\$ 647</u>	<u>\$ 3,492</u>	<u>\$ -</u>	<u>\$ -</u>

(10) Other non-current assets

	June 30, 2026	December 31, 2025	June 30, 2025
Prepayments for equipment	\$ 77,970	\$ 82,671	\$ 21,097
Refundable deposits	64,288	75,600	63,556
Long-term pre-paid payment	-	-	36,856
Long-term prepayments	3,596	7,080	12,893
Prepaid intangible assets	82,703	102,090	101,409
Defined benefit assets	21,273	21,170	2,234
Other non-current assets-	6,696	9,060	10,705
Other			
Less: accumulated impairment	-	-	(30,747)
	<u>\$ 256,526</u>	<u>\$ 297,671</u>	<u>\$ 218,003</u>

The long-term prepaid goods and accumulated impairment are the result of subsidiary Chunghwa Yuming signing the distribution agreement for the new medicine with the vendor, Regulon, in July 2011 with the total amount of EUR 1,800,000. As of December 31, 2017, Chung-Hwa Yuming paid \$36,856 (EUR 900,000), which was recognized as “other non-current assets — long-term prepayments.” However, after evaluation in 2015, Chunghwa Yuming realized the development of such new medicine is not as expected, therefore the recognition of impairment loss of NTD 30,747 was listed.

After seeking legal advice, Chung-Hwa Yuming determined that the estimated costs of international arbitration proceedings would be high and that the current operational and financial status of vendor Regulon remains unknown. Consequently, it was decided to cease pursuit of the payment, and the amount was written off in 2025.

(11) Short-term borrowings

	June 30, 2026	December 31, 2025	June 30, 2025
Financial institution loan			
Secured loans	\$ 1,051,821	\$ 1,084,000	\$ 1,348,751
Credit loan	<u>975,380</u>	<u>923,743</u>	<u>530,800</u>
	<u>\$ 2,027,201</u>	<u>\$ 2,007,743</u>	<u>\$ 1,879,551</u>
Interest rate collars	1.85%~2.545%	1.85%~2.545%	1.75%~2.545%

1. The interest expenses recognized in profit or loss for three months ended June 30, 2026 and 2025 and six months ended June 30, 2026 and 2025 were NTD 9,491, NTD 10,371, NTD 19,871 and NTD 17,512, respectively.
2. By June 30, 2026, December 31 and June 30, 2025, besides the short-term loan amount as stated in Note 8, the Group has issued cashier's checks, respectively, with NTD 2,225,520, NTD 2,541,410 and NTD 1,737,840 as collateral.

(12) Short-term notes payable

	June 30, 2026	December 31, 2025	June 30, 2025
Commercial papers	<u>\$ 30,000</u>	<u>\$ 380,000</u>	<u>\$ 377,000</u>
Interest rate collars	1.85%~1.85%	1.55%~1.82%	1.50%~1.87%

1. The interest expenses recognized in profit or loss for three months ended June 30, 2026 and 2025 and six months ended June 30, 2026 and 2025 were NTD 966, NTD 1,463, NTD 2,810 and NTD 4,549, respectively.
2. The short-term bill is guaranteed by the bills finance company and financial instrument which is issued for short-term capital use, by June 30, 2026, December 31 and June 30, 2025, the cashier's checks have been issued, respectively, with NTD 380,000, NTD 780,000 and NTD 780,000 as collateral for short-term bill receivable.

(13) Other payables

	June 30, 2026	December 31, 2025	June 30, 2025
Salary and bonus payables	\$ 268,463	\$ 346,293	\$ 274,299
Remuneration to employees and directors payable	113,526	69,403	99,000
Accrued expenses	153,952	186,523	191,681
Dividends payable	145,830	-	148,927
Commission payable	21,826	54,380	53,022
Construction equipment amount payable	31,821	34,776	20,899
Other payables	<u>21,355</u>	<u>28,750</u>	<u>24,124</u>
	<u>\$ 756,773</u>	<u>\$ 720,125</u>	<u>\$ 811,952</u>

(14) Long-term borrowings

	June 30, 2026	December 31, 2025	June 30, 2025
Financial institution loan			
Secured loans	\$ 330,400	\$ 240,800	\$ 282,900
Credit loan	<u>-</u>	<u>-</u>	<u>140,000</u>
	330,400	240,800	422,900
Less: long-term borrowing due within 12 months	<u>-</u>	<u>-</u>	<u>(25,200)</u>
	<u>\$ 330,400</u>	<u>\$ 240,800</u>	<u>\$ 397,700</u>
Interest rate collars	1.95%~2.01%	1.95%~2.01%	1.99%~2.23%

1. The interest expenses recognized in profit or loss the three months ended June 30, 2026 and 2025 and six months ended June 30, 2026 and 2025 were NTD 1,486, NTD 1701, NTD

2,649 and NTD 5,566, respectively.

2. The borrowing period for unsecured borrowings and secured borrowings is from 2026 to 2029.
3. The detail for the unused loan amount of the Group is as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Floating annual rate			
Maturing in one year or less	\$ 2,460,359	\$ 2,379,200	\$ 1,957,720
Mature beyond one year	320,000	825,000	1,123,000
	<u>\$ 2,780,359</u>	<u>\$ 3,204,200</u>	<u>\$ 3,080,720</u>

By June 30, 2026, December 31 and June 30, 2025, besides the long-term loan amount as stated in Note 8, the Group has issued cashier's checks, respectively, with NTD 270,000, NTD 720,000 and NTD 1,070,000 as collateral.

(15) Pension

1. (1) The Company and its domestic subsidiaries have a defined benefit pension plan in accordance with the "Labor Standards Act", covering all regular employees' service years prior to the enforcement of the Labor Pension Act on July 1, 2005 and service years thereafter of employees who chose to continue to be subject to the pension mechanism under the Law. When an employee meets the requirements of retirement, the payment of pension is based on service years and the average salary of the six months prior to retirement, with services within 15 years accumulating 2 basis points per year, and service years beyond 15 years accumulating 1 basis point per year up to a maximum of 45 basis points. The company and subsidiary companies provisions 2~6% of total monthly salary to the pension fund in the name of the Pension Supervisory Committee at the Bank of Taiwan. In addition, the Company and subsidiary have the labor pension reserve account balance referred to in the preceding paragraph estimated at the end of each fiscal year. If the account balance is insufficient to pay pension benefit to the employees who qualify for retirement within next year for the pension benefit calculated in the preceding paragraph, the Company and subsidiary will have the spread amount appropriated in a lump sum before the end of March next year.
- (2) For the three months ended June 30, 2026 and 2025 and six months ended June 30, 2026 and 2025, the net pension cost recorded by the company according to the above mentioned pension plans are NTD 27, NTD 287, NTD 52 and NTD 611 respectively.
- (3) The Group has appropriated NTD 2,322 to the pension plan in 2026.
2. (1) Since July 1, 2005, the company and domestic subsidiaries have established definitive provision pension scheme for employees with Taiwan nationality in accordance with the "Labor Pension Act". The Company and its domestic subsidiaries have established a defined contribution pension plan (the "New Plan") under the "Labor Pension Act" covering all regular employees. Under the New Plan, the Group contributes monthly an amount based on 6% of the employees' monthly salaries and wages to an employee's individual pension account at the Bureau of Labor Insurance. The payment of pension benefits is based on an employee's individual pension fund account and the cumulative profit in such account, and employees can choose to receive such pension benefits

monthly or in one lump sum.

- (2) In terms of the pension insurance system of the SCCPC regulated by the government of the People's Republic of China, pension insurance premiums based on a certain percentage of the total salary of local employees are appropriated every month. The ratio are 16% for the three months ended June 30, 2026 and 2025 and six months ended June 30, 2026 and 2025. The pension of each employee is arranged by the government. The Group has no further obligations other than appropriating the pension each month.
- (3) For the three months ended June 30, 2026 and 2025 and six months ended June 30, 2026 and 2025, the net pension cost recorded by the company according to the above mentioned pension plans are NTD 27,341, NTD 25,455, NTD 53,968 and NTD 51,592 respectively.

(16) Share-based payment

1. The Group's share-based payment arrangement for June 30, 2026 is as follows:

<u>Type of arrangement</u>	<u>Grant date</u>	<u>Amount granted (thousand shares)</u>	<u>Contract term</u>	<u>Vesting conditions</u>
New restricted employee shares plan - A	2025.8.8	725	3 years	Note

New restricted employee shares issued by the Group shall be transferred during the vesting period, and they shall not participate in or obtain the following related options before the vesting conditions are met, including but not limited to the right to receive dividends, bonuses, capital reserves, and cash capital increase warrants. If an employee resigns or dies, the new restricted employee shares not yet vested shall be deemed not to meet the vesting conditions on the effective date of resignation or the date of death. The Group will recall the shares without consideration and cancel them.

Note: A portion of the new restricted employee shares vests immediately at 33% after one or two years of service, while the remaining 34% vests after three years of service. The proportion of vested shares is calculated once every three years after the grant. The proportion of vested shares is calculated based on the achievement of the Company's operating performance indicators.

2. Details of the abovementioned share-based payment arrangement are as follows (unit: thousand shares):

	2026	2025
Number of outstanding shares as of January 1 (i.e. June 30)	<u>725</u>	<u>-</u>

The fair value of the new restricted employee shares granted in the current period was measured at the stock closing price on the grant date, August 8, 2025.

3. The share-based payment transactions granted by the Group on the grant date adopted the stock price on the grant date less the performance price to estimate the fair value of stock options; the relevant information is as follows:

Type of arrangement	Grant date	Amount granted (thousand shares)	Stock price (NTD)	Exercise price	Expected volatility	Expected duration	Expected dividend	Risk-free interest rate	Fair value per unit (NTD)
New restricted employee shares plan - A	2025.8.8	725	34.4	-	-	3 years	-	-	34.4

4. The expenses incurred from share-based payment transactions were as follows:

	January 1 to June 30, 2026	January 1 to June 30, 2025
New restricted employee shares	\$ 6,026	\$ -

(17) Capital stock

1. On September 2, 2024, the Company acquired 100% of the equity of CCPC by 0.5 shares of the Company for every 1 share of CCPC. As of June 30, 2026, the Company's authorized capital was NTD 5,000,000, and the actual number of common shares issued was 149,766 thousand shares (including 725 thousand new restricted employee shares), with a paid-in capital of NTD 1,497,656 and a par value of NTD 10 per share.
2. The Company's Board of Directors resolved on August 8, 2025 to issue 725 thousand new restricted employee shares. The base date for the issuance of new shares is August 8, 2025, and the subscription price per share is NTD 0. Except for restricted share transfer rights and the absence of dividend entitlement, the remaining rights and obligations of the common shares under the current issuance are equivalent to those of the issued common shares when employees fulfill the vesting conditions.
3. The beginning and ending outstanding shares for the six months ended June 30, 2026 and 2025 were as follows: (Unit: thousand shares)

	January 1 to June 30, 2026	January 1 to June 30, 2025
January 1	146,141	148,514
Repurchase of treasury stock	(450)	(2,489)
June 30	145,691	146,025

4. The shares possessed by the associate of the Company by June 30, 2026, December 31, 2025 and June 30, 2025 are 21,027 thousand shares.
5. The Company's recovery of treasury stocks is as follows:

Name of holding company	Reasons for recovery	June 30, 2026	
		Number of shares (thousand shares)	Book value
Subsidiaries- Tairung Development Co., Ltd.	Long-term investment	414	\$ 28,054
The Company	for transfer of shares to employees (Note)	3,661	134,248

Name of holding company	Reasons for recovery	December 31, 2025	
		Number of shares (thousand shares)	Book value
Subsidiaries- Tairung Development Co., Ltd.	Long-term investment	414	\$ 28,054
The Company	for transfer of shares to employees (Note)	3,211	118,577
Name of holding company	Reasons for recovery	June 30, 2025	
		Number of shares (thousand shares)	Book value
Subsidiaries- Tairung Development Co., Ltd.	Long-term investment	414	\$ 28,054
The Company	for transfer of shares to employees (Note)	2,602	97,878

Note: On May 5, 2026, August 8, 2025, April 9, 2025 and December 26, 2024, respectively, the Company's Board of Directors resolved to repurchase treasury shares and transfer the shares to employees. The repurchase periods under the aforementioned repurchase plans expired on July 3, 2026, October 9, 2025, June 9, 2025 and February 26, 2025, respectively. In the second quarter of 2026, the Company repurchased 450 thousand treasury shares for NTD 15,671.

- (1) According to the Securities and Exchange Act, the percentage of shares repurchased by the Company shall not exceed 10% of the total number of issued shares, and the total amount of the repurchase shall not exceed the sum of retained earnings plus the premium of issued shares and the realized capital reserve.
 - (2) The treasury stock held by the Company shall not be pledged and shall not be entitled to the rights of shareholders before transfer in accordance with the Securities and Exchange Act.
 - (3) According to the Securities and Exchange Act, the shares repurchased for transfer to employees should be transferred within five years from the date of repurchase. If the shares are not transferred after the expiration date, they should be deemed unissued shares of the Company and canceled for the change of registration.
6. On March 6, 2025, the Company's Board of Directors initially resolved to issue common shares or domestic convertible bonds (including secured or unsecured convertible bonds) through private placement. The actual number of shares to be issued or issuable upon conversion is proposed to be authorized by the shareholders' meeting to the Board of Directors, which shall determine the issuance based on capital market conditions, within a limit not exceeding 20% of the total number of issued shares (i.e., not exceeding 29,953,122 shares). On March 5, 2026, the Board of Directors resolved not to proceed with the aforementioned proposal and, at the same meeting, approved a new private placement of common shares or domestic convertible bonds (including secured or unsecured convertible bonds) under the same terms and conditions. This private placement was approved by the shareholders' meeting on May 26, 2026.

(18) Capital surplus

2026						
	Issuance premium	Treasury stock trade	New restricted employee shares	Others		
				Difference between the actual acquisition or disposal of equity interest in a subsidiary and its book value	Changes in the ownership equity on a subsidiary	Changes in net equity of affiliated enterprises
January 1	\$5,812,204	\$68,389	\$ 17,692	\$ 112	\$ 1,844	\$ 7,606
Difference between the actual acquisition or disposal of equity interest in a subsidiary and its book value	-	-	-	(112)	-	-
June 30	<u>\$5,812,204</u>	<u>\$68,389</u>	<u>\$ 17,692</u>	<u>\$ -</u>	<u>\$ 1,844</u>	<u>\$ 7,606</u>

2025						
	Issuance premium	Treasury stock trade		Others		
				Difference between the actual acquisition or disposal of equity interest in a subsidiary and its book value	Changes in the ownership equity on a subsidiary	
January 1	\$ 5,901,560	\$ 68,087		\$ 112	\$ 1,844	
Distribution of cash from capital reserve	(89,356)	-		-	-	
June 30	<u>\$ 5,812,204</u>	<u>\$ 68,087</u>		<u>\$ 112</u>	<u>\$ 1,844</u>	

1. According to the IFRS Q&A set and Letter (100) Ji-Mi-Zi No. 390 issued by the Accounting Research and Development Foundation dated October 26, 2018, the share exchange transaction between the CCPC on September 2, 2024 was deemed a reorganization under joint control. The Company is a continuation of the CCPC. The Company has reclassified the equity items related to the reorganization of assets and liabilities to the original amount, and the balance of the equity items exceeding the Company's newly issued capital stock and the aforementioned equity items to be deferred are adjusted to increase capital surplus.
2. According to the Company Act, capital reserves from premium income for issuing shares over face values and gift income, not only can offset losses, it can also issue new shares or cash according to the original shareholding when there is no accumulated losses in the company. According to the Securities Transactions Act and its related rules, where capital reserve is applied to supplement capital as above, the total amount cannot exceed 10% of the paid up capital. When the retained earnings of a company is not enough to offset capital

losses, the capital reserves cannot be applied.

(19) Retained earnings

1. According to the Articles of Incorporation of the Company, the dividend policy is planned in consideration of the future capital requirements and long-term financial arrangement and to meet the requirement of cash inflow by the shareholders, if there are any earnings in the general annual report, the tax should be paid firstly and make up for the previous annual losses, then allocate 10% as legal reserve and special reserve based on the regulations, if any earnings are still available, accumulated with the undistributed earnings from the previous year as profit available for distribution, to reserve according to the sales with discretion, and allocate bonus to shareholders, of which the cash dividends shall not be less than 50% of the shareholder bonus and if the cash dividend is less than NTD 0.1, the stock dividends will be issued instead.
2. Legal earnings reserves can only be applied to offset company losses or issue new shares or cash according to the original shareholding ratio, and nothing else. When it is applied to new share or cash issues, the reserve shall exceed 25% of the paid-up capital.
3. (1) In accordance with the regulations, the Company shall set aside special reserve from the debit balance of other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings.
(2) As stated in Note 6(18), the Company is a continuation of CCPC. When it first adopted IFRSs, the Financial Supervisory Commission (FSC) issued Jin-Guan-Zheng-FA-Zi No. 1010012865. On April 6, 2012, which the Company adopts hereafter to implement, the disposal or reclassification of relevant assets is subject to a reversal based on the proportion of the special earned surplus as initially recognized. If the previously stated relevant assets are investment real properties, reversal with disposal or reclassification should be applied for those classified as land. For those assets other than land, the reversal should occur gradually while they are in use.
4. Upon the resolution made by the shareholders on May 26, 2026 and May 27, 2025, the disposition of earnings of the Company for 2025 and 2024 are as follows.

	2025		2024	
	Amount	Dividends per share (\$)	Amount	Dividends per share (\$)
Legal reserve	\$ 24,361		\$ 11,362	
Special reserve	-		33,809	
Cash dividends	145,830	\$ 1.0	59,571	\$ 0.4
	<u>\$ 170,191</u>		<u>\$ 104,742</u>	

The relevant information about the disposition of earnings as above stated which decided by the shareholders can be inquired on the “Market observation post system” of Taiwan Stock Exchange Corporation.

(20) Other equity

2026				
	Unrealized loss of profit valuation	Foreign- currency translations	Unearned Employee Compensation	Total
January 1	(\$ 71,642)	(\$ 82,116)	(\$ 20,083)	(\$ 173,841)
Evaluation adjustment:				
- Group	(21,710)	-	-	(21,710)
- Affiliated enterprises	568	-	-	568
- Valuation adjustment changes to retained earnings	31,449	-	-	31,449
Foreign currency translation differences:				
- Group		53,236	-	53,236
- Tax of the group	-	(10,647)	-	(10,647)
- Affiliated enterprises		165	-	165
Cost of share-based remuneration	-	-	6,026	6,026
June 30	(\$ 61,335)	(\$ 39,362)	(\$ 14,057)	(\$ 114,754)

2025			
	Unrealized loss of profit valuation	Foreign-currency translations	Total
January 1	(\$ 137,597)	(\$ 85,170)	(\$ 222,767)
Evaluation adjustment:			
- Group	(5,470)	-	(5,470)
- Valuation adjustment changes to retained earnings	61,981	-	61,981
Foreign currency translation differences:			
- Group	-	(101,955)	(101,955)
- Tax of the group	-	20,391	20,391
- Affiliated enterprises	-	(453)	(453)
June 30	(\$ 81,086)	(\$ 167,187)	(\$ 248,273)

(21) Operating revenues

	April 1 to June 30, 2026	April 1 to June 30, 2025
Revenue from sales contract	\$ 1,953,642	\$ 2,063,564
Revenue from labor service contract	46,417	43,472
	<u>\$ 2,000,059</u>	<u>\$ 2,107,036</u>

	January 1 to June 30, 2026	January 1 to June 30, 2025
Revenue from sales contract	\$ 4,136,840	\$ 4,279,635
Revenue from labor service contract	92,076	83,029
	<u>\$ 4,228,916</u>	<u>\$ 4,362,664</u>

1. Subdivision of the revenue from contracts with customers

The Group generates revenue by transferring products and labor services to customers either at a point in time or over time. Revenue details are listed as follows:

April 1 to June 30, 2026	Taiwan	China	Other regions	Total
Sales contract	\$ 1,600,066	\$ 313,609	\$ 39,967	\$ 1,953,642
Labor service contract	46,130	287	-	46,417
	<u>\$ 1,646,196</u>	<u>\$ 313,896</u>	<u>\$ 39,967</u>	<u>\$ 2,000,059</u>

April 1 to June 30, 2025	Taiwan	China	Other regions	Total
Sales contract	\$ 1,599,771	\$ 350,589	\$ 113,204	\$ 2,063,564
Labor service contract	43,240	232	-	43,472
	<u>\$ 1,643,011</u>	<u>\$ 350,821</u>	<u>\$ 113,204</u>	<u>\$ 2,107,036</u>

January 1 to June 30, 2026	Taiwan	China	Other regions	Total
Sales contract	\$ 3,305,726	\$ 714,235	\$ 116,879	\$ 4,136,840
Labor service contract	91,789	287	-	92,076
	<u>\$ 3,397,515</u>	<u>\$ 714,522</u>	<u>\$ 116,879</u>	<u>\$ 4,228,916</u>

January 1 to June 30, 2025	Taiwan	China	Other regions	Total
Sales contract	\$ 3,238,294	\$ 836,507	\$ 204,834	\$ 4,279,635
Labor service contract	82,797	232	-	83,029
	<u>\$ 3,321,091</u>	<u>\$ 836,739</u>	<u>\$ 204,834</u>	<u>\$ 4,362,664</u>

2. Contractual liability

The contractual liability relating to the contract with a customer which The Group recognizes is as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Contractual liability- Sales contract of medicine	\$ 42,629	\$ 39,937	\$ 32,409

3. Current income recognized from beginning lease liability for the three months ended June 30, 2026 and 2025 and six months ended June 30, 2026 and 2025 were NTD 5,061, NTD 988, NTD 15,285 and NTD 12,563, respectively.
4. The refund liability which the Group recognized for some goods with right of return is as follows:

	January 1 to June 30, 2026	January 1 to June 30, 2025
January 1	\$ 58,706	\$ 94,638
Increase (decrease) of the current period	(897)	2,211
Used in the current period	(24,067)	(23,431)
June 30	\$ 33,742	\$ 73,418

(22) Interest income

	April 1 to June 30, 2026	April 1 to June 30, 2025
Interest from bank deposits	\$ 1,158	\$ 918
The interest revenue of financial assets at amortized cost	615	660
Other interest incomes	1,449	1,303
	\$ 3,222	\$ 2,881
	January 1 to June 30, 2026	January 1 to June 30, 2025
Interest from bank deposits	\$ 1,489	\$ 983
The interest revenue of financial assets at amortized cost	1,220	1,359
Other interest incomes	2,792	2,856
	\$ 5,501	\$ 5,198

(23) Other income

	April 1 to June 30, 2026	April 1 to June 30, 2025
Rent revenue	\$ 1,745	\$ 1,570
Dividend income	-	2,280
Grant income	1,366	2,602
Other Revenue- other (Note)	119,064	3,150
	<u>\$ 122,175</u>	<u>\$ 9,602</u>
	January 1 to June 30, 2026	January 1 to June 30, 2025
Rent revenue	\$ 3,843	\$ 3,612
Dividend income	-	2,280
Grant income	2,973	4,593
Other Revenue- other (Note)	125,565	4,288
	<u>\$ 132,381</u>	<u>\$ 14,773</u>

Note: For related information, please refer to Contingencies, Note 9(1)1.

(24) Other profits and losses

	April 1 to June 30, 2026	April 1 to June 30, 2025
Gain (loss) in disposal of real estate, plant buildings, equipment & facilities	(\$ 11,052)	\$ 549
Net foreign exchange loss	(828)	(5,136)
Depreciation of investment property	(849)	(807)
Others	(1,120)	533
	<u>(\$ 13,849)</u>	<u>(\$ 4,861)</u>
	January 1 to June 30, 2026	January 1 to June 30, 2025
Gain (Loss) in disposal of real estate, plant buildings, equipment & facilities	(\$ 11,052)	\$ 571
Net foreign exchange loss	(1,465)	(3,354)
Depreciation of investment property	(1,688)	(1,640)
Others	(329)	533
	<u>(\$ 14,534)</u>	<u>(\$ 3,890)</u>

(25) Employees' welfare and depreciation, amortization expenses

Functionality		April 1 to June 30, 2026		
Characteristics	Allocated as operating cost	Employee expenses	Total	
Employee benefits expenses				
Salaries and wages	\$ 174,917	\$ 303,673	\$	478,590
Cost of share-based remuneration	366	2,663		3,029
Labor insurance and national health insurance	18,316	24,035		42,351
Pension expenses	10,362	17,006		27,368
Other employee benefits expenses	11,719	21,322		33,041
Depreciation expenses	57,276	29,770		87,046
Amortization expenses	-	3,326		3,326

Functionality		April 1 to June 30, 2025		
Characteristics	Allocated as operating cost	Employee expenses	Total	
Employee benefits expenses				
Salaries and wages	\$ 158,772	\$ 280,577	\$	439,349
Labor insurance and national health insurance	17,006	21,837		38,843
Pension expenses	9,968	15,774		25,742
Other employee benefits expenses	10,926	16,955		27,881
Depreciation expenses	55,530	28,239		83,769
Amortization expenses	209	2,390		2,599

Functionality		January 1 to June 30, 2026		
Characteristics	Allocated as operating cost	Employee expenses	Total	
Employee benefits expenses				
Salaries and wages	\$ 346,464	\$ 614,418	\$	960,882
Cost of share-based remuneration	728	5,298		6,026
Labor insurance and national health insurance	36,475	49,420		85,895
Pension expenses	20,398	33,622		54,020
Other employee benefits expenses	23,317	43,674		66,991
Depreciation expenses	114,900	58,182		173,082
Amortization expenses	788	4,714		5,502

Characteristics	Functionality		
	January 1 to June 30, 2025		
	Allocated as operating cost	Employee expenses	Total
Employee benefits expenses			
Salaries and wages	\$ 318,646	\$ 567,156	\$ 885,802
Labor insurance and national health insurance	34,620	46,051	80,671
Pension expenses	20,314	31,889	52,203
Other employee benefits expenses	22,521	31,611	54,132
Depreciation expenses	109,759	57,110	166,869
Amortization expenses	277	5,046	5,323

1. According to the Articles of Incorporation, if a balance remains after deducting accumulated losses from the current year's profit, 1% to 15% of the balance shall be appropriated as remuneration to employees, and no more than 3% as remuneration to directors. Of the employee remuneration, no less than 10% shall be allocated to entry-level employees.
 2. (1) The estimated amount of employee remuneration for the three months ended June 30, 2026 and 2025 and the six months ended June 30, 2026 and 2025 was NTD 2,188, NTD 3,900, NTD 4,376 and NTD 7,800, respectively; the estimated amount of director remuneration was NTD 2,000, NTD 1,750, NTD 4,000 and NTD 3,500, respectively. The aforementioned amount was recorded in the account of salary expense.
 (2) The estimated recognition for the six months ended June 30, 2026 is based on the profitability of the year, of which 1.12% for employee bonus and 1.03% for the bonus of the members of the board. The above stated employee bonus is distributed in cash.
 (3) Per the Board of Directors' resolution, the estimated remuneration to employees for 2025 was NTD 17,003 and the estimated remuneration to directors was NTD 7,000, both of which are consistent with the amounts recognized in the financial statements for 2025. The remuneration to employees and directors/supervisors for 2025 had not been paid out.
 3. Information on the employee and remuneration for directors as approved by the board of directors can be found on the Market Observation Post System.
- (26) Financial costs

	April 1 to June 30, 2026	April 1 to June 30, 2025
Interest expenses:		
Bank loan	\$ 11,941	\$ 13,535
Interest expense on the lease liability	1,723	1,801
Interest expense on decommissioning liabilities	17	16
Other Interest expenses	9	(5)
	<u>\$ 13,690</u>	<u>\$ 15,347</u>

	January 1 to June 30, 2026	January 1 to June 30, 2025
Interest expenses:		
Bank loan	\$ 25,330	\$ 27,627
Interest expense on the lease liability	3,455	3,512
Interest expense on decommissioning liabilities	34	33
Other Interest expenses	14	-
	<u>\$ 28,833</u>	<u>\$ 31,172</u>

(27) Income tax

1. Income tax expenses

(1) Components of income tax expense:

	April 1 to June 30, 2026	April 1 to June 30, 2025
Current income tax:		
Current income tax	\$ 44,997	\$ 32,852
Additional levy on undistributed earnings	11,667	3,834
Underestimated (overestimated) income tax in prior periods	(14,239)	3,139
Total Current income tax	<u>42,425</u>	<u>39,825</u>
Deferred income tax:		
Origin and reversal of temporary differences	(12,372)	(3,155)
Total deferred income tax	<u>(12,372)</u>	<u>(3,155)</u>
Income tax expenses	<u>\$ 30,053</u>	<u>\$ 36,670</u>
	January 1 to June 30, 2026	January 1 to June 30, 2025
Current income tax:		
Current income tax	\$ 70,718	\$ 64,570
Additional levy on undistributed earnings	11,667	3,834
Underestimated (overestimated) income tax in prior periods	(14,220)	6,810
Total Current income tax	<u>68,165</u>	<u>75,214</u>
Deferred income tax:		
Origin and reversal of temporary differences	10,730	(9,130)
Total deferred income tax	<u>10,730</u>	<u>(9,130)</u>
Income tax expenses	<u>\$ 78,895</u>	<u>\$ 66,084</u>

(2) Income tax amounts relating to other comprehensive profit and loss:

	April 1 to June 30, 2026	April 1 to June 30, 2025
Exchange differences in overseas operating institutions	(\$ 3,129) January 1 to June 30, 2026	(\$ 25,589) January 1 to June 30, 2025
Exchange differences in overseas operating institutions	\$ 10,647	(\$ 20,391)

2. As the Company was established on September 2, 2024, no profit-seeking enterprise income tax had been approved. The filings of profit-seeking enterprise business income tax returns of the remaining domestic subsidiaries of the Group had been certified by the tax authority up to 2023.

(28) Earnings per share

	April 1 to June 30, 2026		
	After-tax amount	Weighted average outstanding shares (thousand shares)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 179,634	124,344	\$ 1.44
<u>Diluted earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 179,634	124,334	
The impact of potential diluting common stock			
Remuneration to employees	-	125	
New restricted employee shares	-	123	
Net income attributable to the parent company and impact of potential common stock	\$ 179,634	124,582	\$ 1.44

April 1 to June 30, 2025			
	After-tax amount	Weighted average outstanding shares (thousand shares)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 47,334	125,844	\$ 0.38
<u>Diluted earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 47,334	125,844	
The impact of potential diluting common stock			
Remuneration to employees	-	215	
Net income attributable to the parent company and impact of potential common stock	\$ 47,334	126,059	\$ 0.38
January 1 to June 30, 2026			
	After-tax amount	Weighted average outstanding shares (thousand shares)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 375,527	124,352	\$ 3.02
<u>Diluted earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 375,527	124,352	
The impact of potential diluting common stock			
Remuneration to employees	-	305	
New restricted employee shares	-	123	
Net income attributable to the parent company and impact of potential common stock	\$ 375,527	124,780	\$ 3.01

January 1 to June 30, 2025			
	After-tax amount	Weighted average outstanding shares (thousand shares)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 165,328	126,393	\$ 1.31
<u>Diluted earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 165,328	126,393	
The impact of potential diluting common stock			
Remuneration to employees	-	265	
Net income attributable to the parent company and impact of potential common stock	\$ 165,328	126,658	\$ 1.31

(29) Transactions with non controlling interests

Acquisition of additional interests in a subsidiary

On May 18, 2026, the Group acquired an additional 28.32% of the issued shares of its subsidiary, Tai Jung, from key management personnel, Magitech, for cash consideration of NTD 175,050. The carrying amount of the non controlling interests in Tai Jung before the acquisition date was NTD 32,769. The transaction decreased non controlling interests by NTD 32,727 and decreased equity attributable to owners of the parent by NTD 142,323. The effect of changes in the Group's ownership interests in Tai Jung Development Co., Ltd. on equity attributable to owners of the parent for the six months ended June 30, 2026 was as follows:

	January 1 to June 30, 2026
Carrying amount of non-controlling interests acquired	\$ 32,727
Consideration paid to non-controlling interests	(175,050)
Equity of the parent company	(142,323)
Capital surplus- Difference between the actual acquisition or disposal of equity interest in a subsidiary and its book value	112
Adjustment to unappropriated retained earnings due to insufficient capital surplus to offset the difference	(\$ 142,211)

(30) Supplementary information about the cash flows

1. Investing activities partially funded with cash:

	<u>January 1 to June 30, 2026</u>	<u>January 1 to June 30, 2025</u>
Purchase of property, plant, and equipment	\$ 91,940	\$ 72,159
Less: Prepayments for equipment at the beginning of the period (recognized as other non-current assets)	(82,671)	(34,071)
Add: Outstanding payments for equipment at the end of the period (recognized in other non-current liabilities)	77,970	21,097
Add: Construction and equipment payable at the beginning of the period (recognized in other payables)	34,776	38,688
Less: Construction and equipment payable at the Ending of the period (recognized in other payables)	(31,821)	(20,899)
Add: Long-term payables for construction and prepayments for business at the beginning of the period (recognized in other non-current liabilities)	7,160	8,299
Less: Long-term payables for construction and prepayments for business at the end of the period (recognized in other non-current liabilities)	(6,184)	(8,299)
Cash Paid for the Period	<u>\$ 91,170</u>	<u>\$ 76,974</u>

2. Financing activities that did not affect cash flow

	<u>January 1 to June 30, 2026</u>	<u>January 1 to June 30, 2025</u>
Cash dividends payable	<u>\$ 145,830</u>	<u>\$ 148,927</u>

(31) Changes in liability from financial activities.

	Shot-term borrowings	Short-term notes payable	Long-term borrowings	Lease liabilities	Deposits received	Total liabilities from financial activities.
January 1, 2026	\$ 2,007,743	\$ 380,000	\$ 240,800	\$ 357,555	\$ 19,211	\$ 3,005,309
Borrowing/ Increase	889,458	30,000	100,000	18,082	-	1,037,540
Repayment/ Payment (	870,000)	(380,000)	(10,400)	(28,544)	(1,783)	(1,290,727)
Changes from non-cash items	-	-	-	(34)	-	(34)
Changes in exchange rate	-	-	-	1,328	806	2,134
June 30, 2026	<u>\$ 2,027,201</u>	<u>\$ 30,000</u>	<u>\$ 330,400</u>	<u>\$ 348,387</u>	<u>\$ 18,234</u>	<u>\$ 2,754,222</u>

	Shot-term borrowings	Short-term notes payable	Long-term borrowings	Lease liabilities	Deposits received	Total liabilities from financial activities.
January 1, 2025	\$ 1,381,789	\$ 88,992	\$ 1,315,500	\$ 354,275	\$ 28,575	\$ 3,169,131
Borrowing/ Increase	1,084,749	527,008	140,000	46,329	-	1,798,086
Repayment/ Payment (	586,987)	(239,000)	(1,032,600)	(24,414)	(2,396)	(1,885,397)
Changes from non-cash items	-	-	-	(10,608)	-	(10,608)
Changes in exchange rate	-	-	-	(2,810)	(2,360)	(5,170)
June 30, 2025	<u>\$ 1,879,551</u>	<u>\$ 377,000</u>	<u>\$ 422,900</u>	<u>\$ 362,772</u>	<u>\$ 23,819</u>	<u>\$ 3,066,042</u>

7. Related party transactions

(1) Name and relationship of related parties

Name	Relationship with the Group
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB)	Associate of the Group
Sino-Japan Chemical Co., Ltd. (Sino-Japan Chemical)	Associate of the Group
PHERMPEP CO., LTD. (PHERMPEP)	Associate of the Group
Wuxi Jirui Medical Technology Co., Ltd. (Wuxi Jirui)	Associate of the Group
HU-YU CO., LTD (HU-YU)	The individual controlled by major management team of the Group
Markart Enterprise Co., Ltd. (Markart)	The individual controlled by major management team of the Group
Sela Holdings Inc.	The individual controlled by major management team of the Group
Cafe Warm Up Occupational Therapy Center (Cafe Warm Up)	Other related parties
Wang Hsien, I-Chen	Major management team of the Group

(2) Major transactions with related parties

1. Operating revenues

	April 1 to June 30, 2026	April 1 to June 30, 2025
Merchandising:		
One of the individuals controlled by the major management team		
— HU-YU	\$ -	\$ 33,699
Affiliated enterprises	2,280	2,910
	<u>\$ 2,280</u>	<u>\$ 36,609</u>
	January 1 to June 30, 2026	January 1 to June 30, 2025
Merchandising:		
One of the individuals controlled by the major management team		
— HU-YU	\$ 17,788	\$ 79,482
— Markart	-	2
Affiliated enterprises	2,343	2,933
	<u>\$ 20,131</u>	<u>\$ 82,417</u>

- (1) The transaction price for the joint replacement products that CCPC sells is made by the individual controlled by the major management team based on the import cost plus 4%. Due to the industry peculiarities, the payment is Net 240 days which is longer than the general transactions.
- (2) The payment term of the Group for general customers is 120 days to 180 days. Except for the previous statement, the payment term and transaction price for related party is relevant to customers at the same level, however, part of the payment is still being delayed.

2. Purchases

	April 1 to June 30, 2026	April 1 to June 30, 2025
Purchase of goods:		
Affiliated enterprises	<u>\$ 4,269</u>	<u>\$ 4,736</u>
	January 1 to June 30, 2026	January 1 to June 30, 2025
Purchase of goods:		
Affiliated enterprises	<u>\$ 9,662</u>	<u>\$ 20,280</u>

The purchase from the Group to the related party is based on the general commercial conditions, and the payment is 3~4 months with remittance after purchasing. However, part of payment is still delayed.

3. Accounts receivable and notes

	June 30, 2026	December 31, 2025	June 30, 2025
Accounts receivable and notes:			
The individual controlled by major management team- HU-YU	\$ 139,127	\$ 186,572	\$ 105,606
Affiliated enterprises	<u>2,397</u>	<u>15</u>	<u>3,039</u>
	141,524	186,587	108,645
Less: Allowance for losses	<u>(26,029)</u>	<u>(28,676)</u>	<u>(15,841)</u>
Total	<u>\$ 115,495</u>	<u>\$ 157,911</u>	<u>\$ 92,804</u>

- (1) In general, the Company grants payment periods ranging from 120 days to 180 days for general customers, and 240 days for individual entities controlled by the key management. For financial instruments dated beyond the aforementioned payment period, the Board resolved to treat as loans, and has been recognized as “other receivables -related parties”. These loans are accompanied by the letter of surety issued by the Chairman of the Company. For additional information, refer to Note 7 (2) 5 (1), “entities controlled by key management”.
- (2) Account and note receivables as of June 30, 2026, December 31 and June 30, 2025 were from customer contracts. Account receivables and the associated allowed made stood at NTD 244,451 and NTD 36,663, respectively, on January 1, 2025.
- (3) The exposure amounts of the maximum credit risk which can represent the accounts receivable and bill receivable of the Group's related parties without considering the possessed collateral or other credit enhancement condition on June 30, 2026, December 31 and June 30, 2025 are its book amount.
- (4) The aging analysis of accounts receivable and bill receivable is as follows:

	June 30, 2026		December 31, 2025	
	Accounts receivable	Notes receivable	Accounts receivable	Notes receivable
Not-overdue	\$ 33,265	\$ 36,118	\$ 48,422	\$ 109,932
Overdue within 1-90 days	-	66,334	-	28,233
Overdue within 91- 180 days	<u>-</u>	<u>5,807</u>	<u>-</u>	<u>-</u>
	<u>\$ 33,265</u>	<u>\$ 108,259</u>	<u>\$ 48,422</u>	<u>\$ 138,165</u>
			June 30, 2025	
			Accounts receivable	Notes receivable
Not-overdue			<u>\$ 56,291</u>	<u>\$ 52,354</u>

4. Accounts payable

	<u>June 30, 2026</u>	<u>December 31, 2025</u>	<u>June 30, 2025</u>
Accounts payable:			
Affiliated enterprises	<u>\$ 9,614</u>	<u>\$ 9,297</u>	<u>\$ 20,909</u>

The purchase from the Group to the related party is based on the general commercial conditions, and the payment is 3~4 months with remittance after purchasing. However, part of payment is still delayed.

5. Other receivables

(1) A. Related party of the loan funds

	<u>June 30, 2026</u>	<u>December 31, 2025</u>	<u>June 30, 2025</u>
The individual controlled by major management team- HU-YU			
Overdue accounts receivable and notes receivable transferred to other receivables	\$ -	\$ 129,356	\$ 158,286
Financing amount receivable	<u>302,800</u>	<u>91,500</u>	<u>142,000</u>
	302,800	220,856	300,286
Less: Allowance for losses	<u>(40,137)</u>	<u>(31,882)</u>	<u>(23,743)</u>
	<u>\$ 262,663</u>	<u>\$ 188,974</u>	<u>\$ 276,543</u>

B. Interest income

	<u>April 1 to June 30, 2026</u>	<u>April 1 to June 30, 2025</u>
The individual controlled by major management team- HU-YU	<u>\$ 1,231</u>	<u>\$ 1,494</u>
	<u>January 1 to June 30, 2026</u>	<u>January 1 to June 30, 2025</u>
The individual controlled by major management team- HU-YU	<u>\$ 2,451</u>	<u>\$ 2,822</u>

(2) Interest receivable, rent receivable, labor service and collection and payment transfer.

	June 30, 2026	December 31, 2025	June 30, 2025
The individual controlled by major management team-HU-YU	\$ 366	\$ 378	\$ 444
Affiliated enterprises	87	7	8
	<u>\$ 453</u>	<u>\$ 385</u>	<u>\$ 452</u>

6. Acquisition of financial assets

	Account titles in book	Number of shares	Object of transaction	January 1 to June 30, 2026 Prices of acquirements
One of the individuals controlled by the major management team-Markart	Investment under the equity method	1,730	Tairung Enterprise Co., Ltd.	<u>\$ 175,050</u>
				January 1 to June 30, 2025 Prices of acquirements
Affiliate -Wuxi Jirui Medical Technology Co., Ltd.	Investment under the equity method	-	Wuxi Jirui Medical Technology Co., Ltd.	<u>\$ 463</u>

7. Provide the endorsement guarantee status of the related party

	June 30, 2026	December 31, 2025	June 30, 2025
The individual controlled by major management team- HU-YU	<u>\$ 78,200</u>	<u>\$ 250,600</u>	<u>\$ 158,300</u>

The Group's actual guarantee exposure to Hu Yu Co., Ltd. was NTD 78,200.

(3) Remuneration to key management

	April 1 to June 30, 2026	April 1 to June 30, 2025
Short-term employee benefits	\$ 24,153	\$ 24,837
Retirement benefits	281	426
Share-based payment	1,945	-
	<u>\$ 26,379</u>	<u>\$ 25,263</u>

	January 1 to June 30, 2026	January 1 to June 30, 2025
Short-term employee benefits	\$ 47,380	\$ 50,918
Retirement benefits	534	675
Share-based payment	3,889	-
	<u>\$ 51,803</u>	<u>\$ 51,593</u>

8. Pledged assets

The assets of the Group are offered as collateral as follows:

Asset Item	Book Value			Purpose of guarantee
	June 30, 2026	December 31, 2025	June 30, 2025	
Land, buildings and structures (recognized in property, plant, and equipment and investment property)	\$ 2,602,780	\$ 2,635,692	\$ 2,673,092	Long-term and short-term loan, purchase...etc.
Refundable deposits (recognized in other non-current assets)	64,288	75,600	63,556	Leasing security deposits, bid bonds, and court deposits
	<u>\$ 2,667,068</u>	<u>\$ 2,711,292</u>	<u>\$ 2,736,648</u>	

9. Significant contingent liabilities and unrecognized contractual commitments

(1) Contingencies

1. In February 2025, the Company received a letter from the Securities and Futures Investors Protection Center, claiming that the subsidiary CCPC should compensate the counterparty, which the Supreme Court has enforced. . The counterparty settled the above amount in May 2026. The Company no longer has any outstanding receivables, and the matter has been fully completed.
2. In May 2025, SCCPC, a subsidiary of the Group, had a dispute over a technical entrustment development contract with Nanjing Healthnice Pharmaceutical Technology Co., Ltd. ("Nanjing Healthnice"). To develop roxatidine acetate hydrochloride for injection (with a specification of 75 mg), the Company entrusted Nanjing Healthnice with the development of the project, the applications for approval documents for the production permit, commercial mass production, and other technical services. With the Company as the defendant, Nanjing Healthnice required the Company to pay a contract progress payment of NTD 2,919 and overdue interest of NTD 268, and to continue fulfilling the contract's implementation items. In July 2025, the Company filed a counterclaim to require Nanjing Healthnice, the defendant, to cancel the contract and return the technical service fee of NTD 9,749, liquidated damages of NTD 523, and compensation for material costs of NTD 3,743. On February 14, 2026, the Nanjing Jiangbei New Area People's Court, Jiangsu Province ruled that the Company shall pay interest on overdue payment of NTD 18, while Nanjing Healthnice shall return the technical service fee and compensate for material loss totaling NTD 6,282. The other claims of both parties were dismissed. The Group has estimated the relevant receivables in accordance with the first-instance ruling.

Suzhou China Chemical filed an appeal in March 2026, and the case entered second instance proceedings. On July 17, 2026, the judgment in this case was rendered, upholding the original judgment.

(2) Commitments

1. The Company has signed contracts for the purchase of machine and equipment, construction work for the plant, intangible assets and consulting service with outstanding payment amounting to NTD 294,052, NTD 324,471 and NTD 138,618 as of June 30, 2026, December 31 and June 30, 2025, respectively. In the contract of consultation services, part of the performance expenses are paid according to the plan benefits.
2. The unused L/C balance as of June 30, 2026, December 31 and June 30, 2025 were NTD 21,775, NTD 13,360 and NTD 47,426 respectively.
3. The amounts issued as of June 30, 2026, December 31 and June 30, 2025 were NTD 2,875,520, NTD 4,041,410, and NTD 3,587,840, respectively.

10. Significant disaster loss

No such event

11. Significant subsequent events

- (1) The Company's RSAs became effective following approval by the Financial Supervisory Commission on June 5, 2026. On June 25, 2026, the Board of Directors approved the issuance of 814,000 shares, with July 1, 2026 as the record date for the capital increase.

12. Others

(1) Capital management

The Group's capital risk management objectives are to ensure that the Group is capable of continuing operations, to maintain the most appropriate capital structure in order to reduce cost of capital and to maximize returns for shareholders. The Group may make adjustments to dividends paid to shareholders, refund capital to shareholders, issue new shares or sell assets to reduce the level of debts in order to maintain or adjust the Group's capital structure. The Group uses the debt-to-equity ratio to monitor its capital. The ratio is calculated by dividing net debts by total capital. Net debts are calculated as total debts (including "current and non-current borrowings" presented in the consolidated balance sheet) less cash and cash equivalents. Total capital is calculated as "equity" presented in the consolidated balance sheet plus net debts.

The strategy of the Group in 2026 is the same as that in 2025, which is dedicated to maintain the debt-to-capital ratio to 40% below. The debt-to-capital ratio of the Group on June 30, 2026, December 31 and June 30, 2025 were as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Total loan amount	\$ 2,387,601	\$ 2,628,543	\$ 2,679,451
Less: Cash and cash equivalent	(659,756)	(729,497)	(684,064)
Net debt	1,727,845	1,899,046	1,995,387
Total equity	7,677,463	7,611,632	7,384,670
Total capital	<u>\$ 9,405,308</u>	<u>\$ 9,510,678</u>	<u>\$ 9,380,057</u>
Liability/assets ratio	18%	20%	21%

(2) Financial instruments

1. Categories of financial instruments

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Financial assets</u>			
Financial assets at fair value through other comprehensive profit or loss			
Select the designated equity instrument investment.	\$ 119,450	\$ 166,496	\$ 181,419
Financial assets measured at the amortized cost			
Cash and cash equivalents	659,756	729,497	684,064
Financial assets measured at the amortized cost	141,913	134,866	88,414
Notes receivable	334,734	450,915	436,350
Accounts receivable	1,436,382	1,507,307	1,519,733
Other receivables	273,692	205,835	295,221
Finance lease receivables (including current and non-current)	3,817	4,139	-
Refundable deposits (recognized in other non-current assets)	64,288	75,600	63,556
	<u>\$ 3,034,032</u>	<u>\$ 3,274,655</u>	<u>\$ 3,268,757</u>
	June 30, 2026	December 31, 2025	June 30, 2025
<u>Financial liabilities</u>			
Financial liability measured at the amortized cost			
Short-term borrowings	\$ 2,027,201	\$ 2,007,743	\$ 1,879,551
Short-term notes payable	30,000	380,000	377,000
Payable notes	700	807	-
Accounts payable	789,991	750,296	726,719
Other payables	756,773	720,125	811,952
Deposits received	18,234	19,211	23,819
Long-term payables (recognized in other non-current liabilities)	6,184	7,160	8,299
The long-term loan (including the expiration of one year or an operating cycle)			
	330,400	240,800	422,900
	<u>\$ 3,959,483</u>	<u>\$ 4,126,142</u>	<u>\$ 4,250,240</u>
Lease liability (including current and non-current)	<u>\$ 348,387</u>	<u>\$ 357,555</u>	<u>\$ 362,772</u>

2. Risk management policies

- (1) The daily operation of the Group is affected by multiple financial risks, which include the market risk (currency risk, interest rate risk and price risk), credit risk and liquidity risk. The overall risk management policy of the Group is to focus on the unpredictable matters of the financial market and seek for the method to decrease the potential adverse impact on the financial situation and financial performance of the Group.
- (2) The risk management is executed by the financial center of the Group according to the policies approved by the board of directors. The financial center of the group works close with the operation unit of the Group to identify, evaluate and avoid risk. The board of director also sets the written principle for the overall management risk and provides a written policy for specific scope and matters, ex. currency risk, interest rate risk, credit risk, use of derivative and non-derivative financial instruments as well as the investment of the remaining liquidity.

3. Nature and degree of the significant financial risk.

(1) Market Risk

Exchange rate risk

- A. The operation of the Group is transnational, which suffers from the currency occurred by multiple currencies and the majority is USD, RMB and JPY. The relevant currency risk comes from the future commercial deals, recognized assets and liability as well as the net investment of the foreign operation.
- B. The business of the Group involves several non-functional currencies (the functional currency of the Company and some subsidiaries is NTD, while that of some subsidiaries are RMB), and therefore are affected by the exchange rate fluctuation, the information about the currency with significant exchange rate fluctuation is as follows:

June 30, 2026				
		Foreign currency (NTD thousand)	Exchange rate	Book value (NTD)
(Foreign currency: Functional currency)				
<u>Financial assets</u>				
<u>Monetary items</u>				
JPY: NTD	\$	89,488	0.1965	\$ 17,584
USD: NTD		747	31.84	23,784
JPY: RMB		2,423	0.0419	434
USD: RMB		1,029	6.79	29,855
<u>Financial liabilities</u>				
<u>Monetary items</u>				
JPY: NTD	\$	51,261	0.1965	\$ 10,073
USD: NTD		3,246	31.84	103,353

December 31, 2025				
(Foreign currency: Functional currency)	Foreign currency		Exchange rate	Book value
	(NTD thousand)			(NTD)
	<u>Financial assets</u>			
	<u>Monetary items</u>			
JPY: NTD	\$	164,892	0.2007	\$ 33,094
USD: NTD		1,228	31.40	38,559
JPY: RMB		13,340	0.0447	2,548
USD: RMB		827	6.99	24,701
<u>Financial liabilities</u>				
<u>Monetary items</u>				
JPY: NTD	\$	52,685	0.2007	\$ 10,574
USD: NTD		3,958	31.40	124,281

	June 30, 2025			
	Foreign currency (NTD thousand)	Exchange rate	Book value (NTD)	
(Foreign currency: Functional currency)				
<u>Financial assets</u>				
<u>Monetary items</u>				
JPY: NTD	\$ 429,126	0.2037	\$ 87,413	
USD: NTD	1,547	29.28	45,296	
JPY: RMB	18,536	0.0498	3,775	
USD: RMB	3,025	7.16	88,585	
<u>Financial liabilities</u>				
<u>Monetary items</u>				
JPY: NTD	\$ 92,036	0.2037	\$ 18,748	
USD: NTD	2,888	29.28	84,561	

- C. The amounts of the unrealized gains and losses with significant exchange rate fluctuation for the currency of the Group recognized for the three months ended June 30, 2026 and 2025 and six months ended June 30, 2026 and 2025 were summed amount respectively as NTD 2,062, NTD (7,689), NTD 868 and NTD (3,971).
- D. The analysis of foreign exchange risk affected by significant exchange rate fluctuation for the Group is as follows.

January 1 to June 30, 2026			
Sensitivity analysis			
	Magnitude changes	Influence of profit and loss	The impact of other comprehensive profit or loss
(Foreign currency: Functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
JPY: NTD	1%	\$ 176	\$ -
USD: NTD	10%	2,378	-
JPY: RMB	1%	4	-
USD: RMB	10%	2,986	-
<u>Financial liabilities</u>			
<u>Monetary items</u>			
JPY: NTD	1%	\$ 101	\$ -
USD: NTD	10%	10,335	-

January 1 to June 30, 2025			
Sensitivity analysis			
	Magnitude changes	Influence of profit and loss	The impact of other comprehensive profit or loss
(Foreign currency: Functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
JPY: NTD	1%	\$ 874	\$ -
USD: NTD	10%	4,530	-
JPY: RMB	1%	38	-
USD: RMB	10%	8,859	-
<u>Financial liabilities</u>			
<u>Monetary items</u>			
JPY: NTD	1%	\$ 187	\$ -
USD: NTD	10%	8,456	-

Price risk

- A. The equity instrument exposed to price risk of the Group means all financial assets listed in the account at fair value through other comprehensive income. To manage the price risk for the investment of equity instrument, the Group will break down the investment portfolio which is followed by the limited amount set

by the Group.

- B. The Group mainly invests in the domestic listed and unlisted equity instrument, the price of such equity instrument will be affected by the uncertainty of the future value of that investment object. If the price of that equity instrument rises or drops 1%, and all other elements remain the same, the losses or profits of the equity investment classified by fair value through other comprehensive income and financial assets at amortized cost for the six months ended June 30, 2026 and 2025 are, respectively, decreased or increased for NTD 1,195 and NTD 1,814.

Cash flows and the interest risk of fair value

- A. The interest risk of the Group comes from the long-term loan, short-term loan and short-term bills receivable. The Group suffers from the interest rate risk of the cash flows based on the loan issued according to floating rate, part of the risk is being offset with the cash and cash equivalents based on the floating rate. The Group suffers from the interest rate risk of the fair value with the loan issued based on the fixed rate. The loan of the Group is mainly with floating rate. The loan amount of the Group for the six months ended June 30, 2026 and 2025 were based on the floating rate in NTD and US dollars.
- B. For the six months ended June 30, 2026 and 2025, if the change in loan interest rates is 0.1%, and all other elements are remained the same, net incomes for the six months ended June 30, 2026 and 2025 will respectively decreases NTD 1,910 and NTD 1,072 mainly because of the increase or decrease of the interest for the loan of floating interest.

(2) Credit Risk

- A. The credit risk of the Group is the risk deriving from the financial loss caused by the failure of the customers or the counterparties of trade in financial instruments in performing their contractual obligations, and is mainly from the cash flow from the contracts of the account receivable that cannot be settled by the counterparties in accordance with the terms and conditions of payment, and is classified as cash flow from contracts of investment in debt instruments measured on the basis of amortized cost.
- B. The Group established credit risk management in view of a group. According to the credit policy specified internally, before setting the payment, delivery terms and conditions with the new customer, each operating individual in the group should manage and proceed with the credit risk analysis. The internal risk management is to evaluate the credit quality of the customer in consideration of the financial situation, previous experience and other factors. The limited amount of the individual risk is set by the board of director according to the internal or external rating and monitored with the use of the credit line regularly.
- C. The Group adopts IFRS 9 to provide the following assumption as the basis to judge if the credit risk of the financial instrument significantly increases since initial recognition:
- The credit risk of a financial asset is deemed to increase significantly since the recognition when a contract payment is 30 day past due.
- D. The Group adopts IFRS 9 to provide the assumption and based on actual receipt of payment previously that if the payment term in the contract exceeding 91-180 days, it will be considered as violation.
- E. The indicators used by the Group to determine the credit impairment of debt instrument investment are as follows:

- (A) The issuer is likely to enter into bankruptcy or other financial restructuring if it is experiencing major financial difficulties;
 - (B) The issuer makes the active market of the financial asset disappear due to financial difficulties;
 - (C) The issuer delays or fails to pay interest or principal;
 - (D) Changes in national or regional economic conditions that are related to the issuer's default.
- F. The Group classifies the accounts receivable of the customers according to the features of customer type with simplified method to prepare matrix and loss-rate approach as a base to estimate the expected credit loss.
- G. With the recourse process, the Group writes off the receivable amount of the financial assets which can't be expected reasonably, however, the Group will still proceed with the low process for recourse to reserve the equity of liability. By June 30, 2026, December 31 and June 30, 2025, the Group did not have the liability for creditor's with recourse write-off.
- H. The bill receivable and allowance account for change in loss of the Group is as follows:
- (1) The associates of the Group are with excellent credits; therefore, the expected loss rate is 0.2%, and the total carrying amounts of accounts receivable and other receivables as of June 30, 2026, December 31 and June 30, 2025 were NTD 2,397, NTD 15, NTD 3,039, and NTD 87, NTD 7, and NTD 8 respectively, and no allowance for losses was provided.
 - (2) The expected loss rate for the individual of the management team of the Group is 15%, and the total carrying amounts and allowances for loss on June 30, 2026, December 31 and June 30, 2025 are as follows:

Account and note receivables:	June 30, 2026	December 31, 2025	June 30, 2025
One of the individuals controlled by the major management team	\$ 139,127	\$ 186,572	\$ 105,606
Less: Allowance for losses	(26,029)	(28,676)	(15,841)
	<u>\$ 113,098</u>	<u>\$ 157,896</u>	<u>\$ 89,765</u>

Other receivables:	June 30, 2026	December 31, 2025	June 30, 2025
One of the individuals controlled by the major management team	\$ 303,166	\$ 221,234	\$ 300,730
Less: Allowance for losses	(40,137)	(31,882)	(23,743)
	<u>\$ 263,029</u>	<u>\$ 189,352</u>	<u>\$ 276,987</u>

- (3) The Group adjusts the loss rate established according to the historical and current information in a specific period of time in consideration of the completeness of vision, to estimate the bill receivable and allowance for loss. The prepared matrix of June 30, 2026, December 31 and June 30, 2025 are as follows:

	Not-overdue	1 to 90 days overdue	91 to 180 days overdue	Overdue exceeding 181 days	Total
June 30, 2026					
Expected rate of loss	0.01%~1.05%	0.02%~10.08%	0.02%~100%	100%	
Total amount of the book value	\$ 1,731,882	\$ 47,727	\$ 4,510	\$ 3,083	\$ 1,787,202
Allowance for losses	2,265	2,443	3,060	3,083	10,851
December 31, 2025					
Expected rate of loss	0.01%~1.05%	0.02%~10.08%	0.02%~100%	100%	
Total amount of the book value	\$ 1,906,819	\$ 42,328	\$ 4,320	\$ 3,207	\$ 1,956,674
Allowance for losses	4,155	2,135	2,254	3,207	11,751
June 30, 2025					
Expected rate of loss	0.02%~0.5%	0.02%~11.76%	0.02%~100%	100%	
Total amount of the book value	\$ 1,973,934	\$ 21,854	\$ 7,868	\$ 2,808	\$ 2,006,464
Allowance for losses	3,395	995	2,788	2,808	9,986

- I. The change in allowance for loss table for bill receivable, accounts receivable and other accounts receivable by the Group are as follows:

	2026	
	Note receivable and accounts receivable	Other receivables
January 1	\$ 40,427	\$ 31,882
Recognition of impairment loss	4,449	-
Reclassification	(8,255)	8,255
Foreign exchange impact amount	259	-
June 30	\$ 36,880	\$ 40,137

	2025	
	Note receivable and accounts receivable	Other receivables
January 1	\$ 48,816	\$ 23,901
Impairment loss reversal	(22,534)	-
Reclassification	158	(158)
Foreign exchange impact amount	(613)	-
June 30	<u>\$ 25,827</u>	<u>\$ 23,743</u>

- J. The Group's credit risk rating information for assets measured at amortized cost is as follows:
June 30, 2025: none.

	June 30, 2026			
	By duration			
	By 12 months	Those for whom credit risk has increased significantly	Those with impaired credit risk	Total
Financial assets measured at the amortized cost	<u>\$ 141,913</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 141,913</u>

	December 31, 2025			
	By duration			
	By 12 months	Those for whom credit risk has increased significantly	Those with impaired credit risk	Total
Financial assets measured at the amortized cost	<u>\$ 134,866</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 134,866</u>

	June 30, 2025			
	By duration			
	By 12 months	Those for whom credit risk has increased significantly	Those with impaired credit risk	Total
Financial assets measured at the amortized cost	<u>\$ 88,414</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 88,414</u>

(3) Liquidity risk

- A. The prediction of cash flows is executed by each operating unit in the group and summarized by the financial center of the Group. The financial center of the

group monitors the prediction for the liquidity requirement of the Group, to ensure the capital is sufficient to support the operation requirements.

- B. The below table is the derivative financial liabilities of the Group, which is classified based on the due date. The derivative financial liabilities are analyzed according to the remaining period between the date of balance sheet to the expiry date of the contract. The amount of the cash flows in the contract disclosed by the following table is the undiscounted amount.

Non-derivative financial liabilities:

	Less than 3 months	3 months to 1 year	1 to 2 years	2 to 5 years	Over 5 years
June 30, 2026					
Shot-term borrowings	\$ 1,056,425	\$ 978,548	\$ -	\$ -	\$ -
Short-term notes payable	-	30,000	-	-	-
Payable notes	700	-	-	-	-
Accounts payable	680,790	109,201	-	-	-
Other payables	682,983	73,790	-	-	-
Lease liabilities	16,748	48,554	70,358	142,611	92,782
Long-term payables (recognized in other non-current liabilities)	-	-	1,953	4,231	-
Long-term borrowings	1,807	763	304,113	28,433	-
Deposits received	130	17,386	718	-	-
Financial commitment agreements	78,200	-	-	-	-

Non-derivative financial liabilities:

	Less than 3 months	3 months to 1 year	1 to 2 years	2 to 5 years	Over 5 years
December 31, 2025					
Shot-term borrowings	\$ 502,238	\$ 1,511,234	\$ -	\$ -	\$ -
Short-term notes payable	380,000	-	-	-	-
Payable notes	807	-	-	-	-
Accounts payable	585,147	165,149	-	-	-
Other payables	678,954	41,171	-	-	-
Lease liabilities	15,423	45,323	65,737	145,739	110,994
Long-term payables (recognized in other non-current liabilities)	-	-	1,953	5,207	-
Long-term borrowings	1,051	180,921	22,122	41,881	-
Deposits received	130	18,363	718	-	-
Financial commitment agreements	178,300	-	-	-	-

Non-derivative financial liabilities:

	Less than 3 months	3 months to 1 year	1 to 2 years	2 to 5 years	Over 5 years
June 30, 2025					
Shot-term borrowings	\$ 545,836	\$ 1,338,565	\$ -	\$ -	\$ -

Short-term notes payable	377,000	-	-	-	-
Accounts payable	625,318	101,401	-	-	-
Other payables	770,657	41,295	-	-	-
Lease liabilities	14,157	42,826	62,698	141,904	129,127
Long-term payables (recognized in other non-current liabilities)	-	-	1,953	5,858	488
Long-term borrowings	1,830	26,758	372,468	31,709	-
Deposits received	-	22,487	1,332	-	-
Financial commitment agreements	158,300	-	-	-	-

(3) Fair value information

- For the Group's financial assets and liabilities not measured at fair value, including cash and cash equivalents, financial assets measured at amortized cost — non-current, bills receivable, accounts receivable, other receivables, finance lease receivables (including current and non-current), refundable deposits, short-term borrowings, short-term bills payable, notes payable, accounts payable, other payables, deposits received, long-term payables, long-term borrowings (including long-term borrowings due within one year or within the Group's operating cycle) and lease liabilities (including current and non-current), the amount is a reasonable approximation of fair value. Please refer to Note 12 (2) 1. for details.
- The valuation technique for measuring the fair value of financial and non-financial instruments is defined as follows:
 - Level 1: The quotation (unadjusted) of the same assets or liabilities that can be acquired by the company in an active market on the measurement date. An active market refers to the market with sufficient frequency and quantity of the assets or liabilities transactions took place in order to provide market pricing information constantly. The fair value of the stock investment for the listed stock invested by the Group is all included.
 - Level 2: It refers to the directly or indirectly observable input value of asset or liability, except for those quotations included in Level 1. The fair value of structured deposits invested by the Group and embedded in derivatives is within this level.
 - Level 3: The unobservable inputs of assets or liabilities.
- The fair values of investment property calculated by the cost method as of June 30, 2026, December 31 and June 30, 2025 were NTD 218,093, NTD 208,108 and NTD 206,254, respectively; these fair values were estimated based on market prices of similar properties in the vicinity.
- The Group's financial and non-financial instruments measured at fair value are classified by the nature of assets and liabilities, characteristics and risks, and fair value as follows:
 - The relevant information about the classification of the nature for the assets and liabilities of the Group is as follows:

June 30, 2026	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Repeatable fair value</u>				
Investment of equity instruments at fair value through other comprehensive income	<u>\$ 36,907</u>	<u>\$ -</u>	<u>\$ 82,543</u>	<u>\$119,450</u>
December 31, 2025	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Repeatable fair value</u>				
Investment of equity instruments at fair value through other comprehensive income	<u>\$ 63,792</u>	<u>\$ -</u>	<u>\$102,704</u>	<u>\$166,496</u>
June 30, 2025	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Repeatable fair value</u>				
Investment of equity instruments at fair value through other comprehensive income	<u>\$ 97,800</u>	<u>\$ -</u>	<u>\$ 83,619</u>	<u>\$181,419</u>

(2) The methods and assumptions used by the Group to measure fair value are described as follows:

A. The Group adopts the market quotation as the input value for the fair value (which is the first class), the classification according to the feature of the tool is as follows:

	<u>Listed (OTC) and emerging stocks</u>
Market quotation	<u>Closing price</u>

B. Besides the financial instrument of the active market as stated above, the fair value of other financial instrument is obtained by evaluation technique or reference of the counter party.

C. While evaluating the financial instrument which is non-standardized and with low complexity, the Group adopts the evaluation technique which is comprehensively used by the market participants. The parameter used for the valuation model of such financial instrument is usually the observable information of the market.

D. What the valuation model comes out is the estimated value, and the evaluation technique can't reflect all relating factors of the financial instrument and non-financial instrument of the Group. Therefore, the estimated value of the valuation model will be adjusted based on the additional parameter properly, such as the

model risk or liquidity risk...etc. According to the management policy and relevant control program of the valuation model for fair value of the Group, the management team believes it is appropriate and necessary to adjust the evaluation for expressing the fair value of the financial instrument and non-financial instrument in the aggregate balance sheet. The price information and parameter used in the valuation process is evaluated prudently and adjusted according to the current market situation properly.

5. The changes in Level 3 for the six months ended June 30, 2026 and 2025, respectively, are described as follows:

	2026	2025
	Equity instruments	Equity instruments
January 1	\$ 102,704	\$ 98,423
Increase of the current period	16,060	97
Evaluation adjustment	(28,435)	(11,022)
Capital reduction and refund of the equity instruments measured at fair value through other comprehensive income	(7,442)	-
Foreign exchange impact amount	(344)	(3,879)
June 30	<u>\$ 82,543</u>	<u>\$ 83,619</u>

6. The valuation process for classifying the fair value to the third level of the Group is proceeded by the financial center for the independent fair value valuation of the financial instrument, by using the independent sources to have the valuation result close to the market status, and make sure that the sources of the information is independent, reliable and consistent with other resources as well as all other necessary adjustment of fair value, to ensure the valuation result is reasonable.

Besides, the valuation policy, valuation process and confirmation for the fair value of the financial instrument set by the Ministry of Finance meet the regulations of relevant international financial reporting standards.

7. The sensitivity analysis explanation of the quantitative data of significant non-observable input value and change of significant non-observable input value which belongs to the valuation model for the items to review the third level of fair value is as follows:

	June 30, 2026			
	Fair value	Valuation technique	Significant unobservable input value	Relationship between input value and fair value
Stock of the venture capital	\$ 82,543	Net assets value method	Not applicable	Not applicable
	December 31, 2025			
	Fair value	Valuation	Significant	Relationship

		<u>technique</u>	<u>unobservable input value</u>	<u>between input value and fair value</u>
Stock of the venture capital	\$ 102,704	Net assets value method	Not applicable	Not applicable
	<u>June 30, 2025</u>			
	<u>Fair value</u>	<u>Valuation technique</u>	<u>Significant unobservable input value</u>	<u>Relationship between input value and fair value</u>
Stock of the venture capital	\$ 83,619	Net assets value method	Not applicable	Not applicable

8. The valuation and valuation parameter chosen by the Group is evaluated properly, however, the different valuation model or valuation parameter may lead in different valuation result.

13. Notes of disclosure

(1) Information about important transactions

According to the “Regulations Governing the Preparation of Financial Reports by Securities Issuers.” The significant transaction matters of The Company for the six months ended June 30, 2026 were as follows:

1. The Loaning of funds: please see attached table 1.
2. Endorsement and Guarantee: please see attached table 2.
3. Major securities held at the end of the period (excluding investments in subsidiaries, affiliates, and joint ventures): Please see attached table 3.
4. Purchase/sale amount of transactions with related parties reaching NTD 100 million or more than 20% of the paid-in capital: please see the attached table 4.
5. Amounts receivable from related parties totaling more than NTD 100 million or 20% of paid up capital: please see attached table 5.
6. Business relationships and significant transactions between the parent company and its subsidiaries: Please refer to attached table 6.

(2) Information related to reinvested enterprises

The relevant information of names, area of location of the investees (excluding the investees in China), please see attached table 7.

(3) Information about investment in mainland China

1. Basic information: Please see attached table 8.
2. Significant transactions with investee companies in the Mainland China, either directly or indirectly through a third country: Not applicable.

14. Segment information

(1) General information

The management team of The Company has identified the reportable segments according to the information used in making decision by the board of director.

The board of director of the Group operates and evaluates the segments performance in view of the regional diversity.

(2) Segment information

The information provided for the major operation decision maker for the reportable segments is as follows:

<u>April 1 to June 30, 2026</u>	<u>Taiwan</u>	<u>China</u>	<u>Adjust and eliminate</u>	<u>Total</u>
External revenue	\$ 1,670,640	\$ 329,419	\$ -	\$ 32,000,059
Inter-segment income	711,468	-	(711,468)	-
Revenue of the reportable segments	<u>\$ 2,382,108</u>	<u>\$ 329,419</u>	<u>(\$ 711,468)</u>	<u>\$ 2,000,059</u>
Pre-tax net income of the segments before being adjusted	\$ 199,481	(\$ 11,402)	(\$ 7,806)	\$ 180,273
Investment profit or loss recognized according to the Equity Method	184,534	(6)	(152,993)	31,535
Pre-tax net income of the reportable segments	<u>\$ 384,015</u>	<u>(\$ 11,408)</u>	<u>(\$ 160,799)</u>	<u>\$ 211,808</u>
Profits or losses of the segments include: Depreciation and amortization	<u>\$ 75,259</u>	<u>\$ 15,962</u>		<u>\$ 91,221</u>
<u>April 1 to June 30, 2025</u>	<u>Taiwan</u>	<u>China</u>	<u>Adjust and eliminate</u>	<u>Total</u>
External revenue	\$ 1,733,475	\$ 373,561	\$ -	\$ 2,107,036
Inter-segment income	739,815	-	(739,815)	-
Revenue of the reportable segments	<u>\$ 2,473,290</u>	<u>\$ 373,561</u>	<u>(\$ 739,815)</u>	<u>\$ 2,107,036</u>
Pre-tax net income of the segments before being adjusted	\$ 269,750	(\$ 40,281)	(\$ 131,401)	\$ 98,068
Investment profit or loss recognized according to the Equity Method	73,928	(2,255)	(85,925)	(14,252)
Pre-tax net income of the reportable segments	<u>\$ 343,678</u>	<u>(\$ 42,536)</u>	<u>(\$ 217,326)</u>	<u>\$ 83,816</u>
Profits or losses of the segments include: Depreciation and amortization	<u>\$ 74,971</u>	<u>\$ 12,204</u>		<u>\$ 87,175</u>

<u>January 1 to June 30,</u> <u>2026</u>	Taiwan	China	Adjust and eliminate	Total
External revenue	\$ 3,490,846	\$ 738,070	\$ -	\$ 4,228,916
Inter-segment income	<u>1,360,896</u>	<u>-</u>	<u>(1,360,896)</u>	<u>-</u>
Revenue of the reportable segments	<u>\$ 4,851,742</u>	<u>\$ 738,070</u>	<u>(\$ 1,360,896)</u>	<u>\$ 4,228,916</u>
Pre-tax net income of the segments before being adjusted	\$ 339,921	\$ 33,661	\$ 10,834	\$ 384,416
Investment profit or loss recognized according to the Equity Method	<u>453,668</u>	<u>(8)</u>	<u>(384,437)</u>	<u>69,223</u>
Pre-tax net income of the reportable segments	<u>\$ 793,589</u>	<u>\$ 33,653</u>	<u>(\$ 373,603)</u>	<u>\$ 453,639</u>
Asset of the reportable segments	<u>\$ 10,806,171</u>	<u>\$ 1,524,876</u>		<u>\$ 12,331,047</u>
Profits or losses of the segments include:				
Depreciation and amortization	<u>\$ 150,263</u>	<u>\$ 30,009</u>		<u>\$ 180,272</u>
<u>January 1 to June 30,</u> <u>2025</u>	Taiwan	China	Adjust and eliminate	Total
External revenue	\$ 3,487,429	\$ 875,235	\$ -	\$ 4,362,664
Inter-segment income	<u>1,437,732</u>	<u>-</u>	<u>(1,437,732)</u>	<u>-</u>
Revenue of the reportable segments	<u>\$ 4,925,161</u>	<u>\$ 875,235</u>	<u>(\$ 1,437,732)</u>	<u>\$ 4,362,664</u>
Pre-tax net income of the segments before being adjusted	\$ 424,321	(\$ 54,544)	(\$ 131,011)	\$ 238,766
Investment profit or loss recognized according to the Equity Method	<u>280,096</u>	<u>(2,257)</u>	<u>(285,160)</u>	<u>(7,321)</u>
Pre-tax net income of the reportable segments	<u>\$ 704,417</u>	<u>(\$ 56,801)</u>	<u>(\$ 416,171)</u>	<u>\$ 231,445</u>
Asset of the reportable segments	<u>\$ 10,945,816</u>	<u>\$ 1,405,942</u>		<u>\$ 12,351,758</u>
Profits or losses of the segments include:				
Depreciation and amortization	<u>\$ 149,007</u>	<u>\$ 24,825</u>		<u>\$ 173,832</u>

(3) The adjusted information of the profits or losses of the segments

The pre-tax profit/ loss of the reportable segments is the same as that of the business segments, therefore, no adjustment has to be made.

Centra Inc. and subsidiaries

The Loaning of Funds

January 1 to March 31, 2026

Attached table 1

Unit: NTD thousand
(Except where otherwise stated)

No. (Note 1)	The lender of fund	The borrower of fund	Transaction title	Are they related parties	Maximum balance – current period (Note 2)	Balance, ending	The actual amounts disbursed	Interest rate collars	Nature of financing (Note 3)	Amount of business transactions	Reasons for the necessity of short-term financing	Amount of provision for bad debts	Collateral		Limit of financing particular beneficiary	Total limit of financing	Remarks
													Name	Value			
1	China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Senior Lifestyle Services Co. Ltd.	Other receivables	Y	\$ 20,000	\$ 20,000	\$ -	2.10%	2	\$ -	Working capital			\$ -	\$ 1,069,633	\$ 2,139,266	Note 4 (2)
1	China Chemical & Pharmaceutical Co., Ltd.	HU-YU Co., Ltd.	Other receivables	Y	157,589	-		2.01%	1	117,872	-	22,587		-	117,872	2,139,266	Note 4 (1), (2) and Note 5
1	China Chemical & Pharmaceutical Co., Ltd.	HU-YU Co., Ltd.	Other receivables	Y	140,000	140,000	140,000	2.01%	2	-	Working capital			-	1,069,633	2,139,266	Note 4(4), Note 5
2	Tairung Enterprise Co., Ltd.	HU-YU Co., Ltd.	Other receivables	Y	46,000	45,800	45,800	2.30%	2	-	Working capital	-		-	38,210	38,210	Note 4(4), Note 5
3	Chunghwa Yuming Healthcare Co., Ltd.	HU-YU Co., Ltd.	Other receivables	Y	117,000	117,000	117,000	2.10%	2	-	Working capital	17,550		-	97,830	195,661	Note 4(5), Note 5
4	Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd.	Other receivables	Y	50,393	36,948	36,948	-	2	-	Working capital	-		-	192,732	385,463	Note 4 (3)

Note 1: The filing method for the numbering of lending money by the Company is as follows:

(1) Fill in 0 for the issuer.

(2) The investees are sequentially numbered from 1 and so forth.

Note 2: Maximum balance of financing a third party in current period.

Note 3: Below are the two filing methods for the nature of lending money

(1) With business dealings

(2) With necessity of short-term financing

Note 4: Maximum and aggregate amount of loans made to a single entity by the Company:

(1) Company and its subsidiaries with business transactions with the company whose individual lending amount may not exceed the most recent one year or the current year's incoming goods amount or total sales amount with the company, at the time of capital lending.

(2) No loan made to a single entitle by China Chemical & Pharmaceutical Co., Ltd. shall exceed 15% of its net worth. Aggregated loans made shall not exceed 30% of its net worth.

(3) No loan made to a single entitle by Chunghwa Yuming shall exceed 15% of its net worth. Aggregated loans made shall not exceed 30% of its net worth.

(4) No loan made to a single entitle by Tairung Enterprise Co., Ltd. shall exceed 40% of its net worth. Aggregated loans made shall not exceed 40% of its net worth.

(5) No loan made to a single entitle by Chunghwa Yuming Healthcare Co. shall exceed 15% of its net worth. Aggregated loans made shall not exceed 30% of its net worth.

Note 5: The full value guarantee will be provided by the Chairman of The Company

Cenra Inc. and subsidiaries
Endorsements and guarantees made for others
January 1 to March 31, 2026

Attached table 2

Unit: NTD thousand
(Except where otherwise stated)

No. (Note 1)	The company providing the endorsement and/or guarantee	The party receiving the endorsement and/or guarantee		The limit of endorsements and/or guarantees to a single business entity	The highest balance of endorsements and/or guarantees in the current period	The ending balance of endorsements and/or guarantees	The actual amounts disbursed	Amount of property pledged for endorsements /guarantees	Total endorsements and guarantees as a percentage of equity in the most recent financial statement	The upper limit of an endorsement and/or guarantee	Guarantee and endorsement of parent company to subsidiary	Guarantee and endorsement by subsidiary to parent company	Guarantee and endorsement in Mainland China	Remarks
		Company name	Relation (Note 2)											
1	China Chemical & Pharmaceutical Co., Ltd.	HU-YU Co., Ltd.	1	\$ 117,872	\$ 250,600	\$ 78,200	\$ 51,900	\$ -	1.10%	\$3,565,443	N	N	N	Note 3, 4, 5 and 6

Note 1: The column for numbering is elaborated below:

- (1) Fill in 0 for the issuer.
- (2) The investees are sequentially numbered from 1 and so forth.

Note 2: The 6 types of relations between the endorsement/ guarantee provider and subject of endorsement/ guarantee are as follows. Indication of types is applicable.

- (1) Business relation.
- (2) Subsidiary owns over 50% of ordinary equity share with direct possession.
- (3) The aggregation of the ordinary share possessed by The Company and its Subsidiary exceeds 50% by the investee.
- (4) The Parent Company which possesses more than 50% of the ordinary equity share directly or through its Subsidiary with indirect possession.
- (5) For building construction, The Company holds a mutual guarantee with other companies based on the peer agreement:
- (6) Due to the joint investment relationship, shareholders are to provide endorsement and guarantee to the company proportionately to the respective shareholding ratio.

Note 3: Endorsement and guarantee to a particular enterprise shall not exceed 30% of the net worth of the CCPC. The limit of endorsement and guarantee to companies in business transactions with the CCPC shall not exceed the amount of purchase or sale with the CCPC in the previous period or current period at the time of endorsement and guarantee, whichever is higher.

Note 4: The endorsement/ guarantee amount of the CCPC is limited to 50% of the net value of the CCPC.

Note 5: Included in the maximum balance of endorsements and guarantees was \$ 72,300 arising from the renewal contract having been submitted to the Board of Directors for approval prior to the expiration of the original contract. The actual guarantee exposure undertaken by CCPC on behalf of Hu Yu Co., Ltd. was \$ 178,300.

Cenra Inc. and subsidiaries

Major securities held at the end of the period (excluding investments in subsidiaries, associates, and joint ventures)

March 31, 2026

Attached table 3

Unit: NTD thousand
(Except where otherwise stated)

Holding company	Types of negotiable securities	Names of negotiable securities (Note 1)	Relationship with the securities issuer	Account titles in book	At ending				
					Number of shares	Book value	Ratio of Shareholding	Fair value	Remarks
China Holdings Co., Ltd.	Equity	Eterna Capital	-	Investment of equity instruments at fair value through other comprehensive income	-	\$ 15,920	8.77%	\$ 15,920	None
China Chemical & Pharmaceutical Co., Ltd.	Stock	Green Management International Co., Ltd.	-	"	111,237	1,954	5.21%	1,954	"
	"	CDIB Capital Healthcare Ventures Limited	-	"	2,434,286	11,220	1.71%	11,220	"
	"	MegaPro Biomedical Co., Ltd.	Other related parties	"	2,938,458	36,907	3.70%	36,907	"
	Equity	Seraph partners	-	"	-	8,897	2.96%	8,897	"
Tairung Enterprise Co., Ltd.	Stock	Cenra Inc.	The Company	"	413,941	14,467	0.28%	14,467	None
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Equity	Kunshan CDIB Yida Healthcare Enterprise Ltd.	-	"	-	44,552	2.37%	44,552	None

Note 1: Securities as stated in this table are the stocks, bonds, beneficiary certificates and the securities deriving from the above items within the scope of IFRS 9, "Financial Instruments"

Note 2: The Company determines the securities to be listed in accordance with the principle of materiality and does not disclose the securities with a carrying amount of less than NTD 1,000.

Cenra Inc. and subsidiaries

Purchase from or sale to related parties for an amount exceeding NTD 100 million or 20% of paid-in capital

January 1 to March 31, 2026

Attached table 4

Unit: NTD thousand

Purchase (sale) company	Name of counterparty	Relation	Transactions				Trading terms different from general trade and reasons		Notes and accounts receivable (payable)		Remarks
			Purchase (sale)	Amount	Percentage of total purchase (sale)	The credit period	Unit price	The credit period	Balance	Percentage of total notes and accounts receivable (payable)	
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Yuming Healthcare Co., Ltd.	Subsidiaries	Sale	\$ 1,356,455	70.16%	The payment term is 150 days	Agreed by the quotation in the purchase agreement signed by both parties.	The payment term is 150 days.	\$ 1,739,641	78.77%	

Note: Individual accounts payable transactions less than NTD 100,000 will not be disclosed.

Cenra Inc. and subsidiaries

Accounts receivable from related parties for an amount exceeding NTD 100 million or 20% of paid-in capital

March 31, 2026

Attached table 5

Unit: NTD thousand

(Except where otherwise stated)

The company booked in the receivables	Name of counterparty	Relation	Receivables from related party	Turnover rate	Overdue Receivables from related parties		Receivables amount collected from related parties subsequently	Amount of provision for bad debts	Remarks
					Amount	Process			
China Chemical & Pharmaceutical Co., Ltd.	HU-YU Co., Ltd.	The Chairman is the same person of The Company.	\$ 279,336	0.12	\$ -	To obtain the proven guarantee from the chairman of The Company and take joint and several liability for the unpaid debts or bills.	\$ 6.663	\$ 48,616	
"	Chunghwa Yuming Healthcare Co., Ltd.	Subsidiaries	1,739,641	1.55	643,547	Active debt collection.	321,050	-	

Cenra Inc. and subsidiaries

Business relationships and significant transactions between parent company and subsidiaries

January 1 to March 31, 2026

Attached table 6

Unit: NTD thousand
(Except where otherwise stated)

No. (Note 1)	Trader's name	Counterparty	Affiliation to trader (Note 2)	Transactions			Percentage in consolidated total revenue or total assets (Note 3)
				Title	Amount	Terms and conditions	
1	CCPC	Chunghwa Yuming Healthcare Co., Ltd.	3	Sale	\$ 1,356,455	Note 4	32.08%
1	"	"	3	Accounts receivable	1,739,641	"	14.11%

Note 1: The information about transactions between parent company and subsidiaries shall be numbered and noted in the following manner in the box of numbers:

- (1) Fill in "0" for parent company.
- (2) Subsidiaries are numbered from number 1.

Note 2: There are three types of relationships with traders, please mark the type intended.

- (1) Parent company vs. subsidiaries.
- (2) Subsidiaries vs. parent company.
- (3) Subsidiaries vs. subsidiaries.

Note 3: For computing the ratio of trade amount to total sales revenue or total assets, if it is for asset and liability account, the computation is based on the ratio of ending balance to total consolidated assets; however, if it is for income and expense account, the computation is based on the ratio of interim cumulative amount to total consolidated revenue.

Note 4: The selling price is agreed to by the quotation in the purchase agreement signed by both parties. The payment of the selling goods is 150 days.

Note 5: The significant matters between the parent company and subsidiaries have been written off.

Note 6: The amount of individual deal below NTD 100,000 will not be disclosed.

Cenra Inc. and subsidiaries

The relevant information of names, area of location of the investees (excluding the investees in China)

January 1 to March 31, 2026

Attached table 7 Unit: NTD thousand
(Except where otherwise stated)

Investor	Name of investee	Location	Principal business	Sum of initial investment		Ending shareholding			Current period profit / loss of the investee	Recognized investment income	Remarks
				Current period-end	The end of last year	Number of shares	Ratio	Book value			
Cenra Inc.	China Chemical & Pharmaceutical Co., Ltd.	Taiwan	Manufacture and sales of Western medicine preparations and health-care articles.	\$ 6,747,063	\$ 6,747,063	234,890,949	100.00	\$ 7,024,327	\$ 272,519	\$ 283,096	Subsidiaries
Cenra Inc.	Providence Investments Inc.	Taiwan	General investment businesses	25,000	25,000	2,500,000	100.00	25,124	47	47	Subsidiaries
Cenra Inc.	Chunghwa Yuming Healthcare Co., Ltd.	Taiwan	Wholesale of medicine and medical equipment	688,485	688,485	29,590,000	100.00	652,202	87,326	87,326	Subsidiaries
China Chemical & Pharmaceutical Co., Ltd.	Tairung Enterprise Co., Ltd.	Taiwan	Manufacture and sales of glass, plastics made containers	259,647	226,920	6,106	99.96	95,231	(21,914)	-	Sub-subsidary (Note 1)
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Holding Co., Ltd	Cayman Islands	Professional investment company	910,384	910,384	44,485,000	100.00	1,273,132	28,493	-	Sub-subsidary (Note 1)
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Senior Lifestyle Services Co. Ltd.	Taiwan	Medicine, wholesale of medicine equipment and home care service	354,400	354,400	5,000,000	100.00	(3,464)	(1,143)	-	Sub-subsidary (Note 1)
China Chemical & Pharmaceutical Co., Ltd.	Sino-Japan Chemical Co., Ltd.	Taiwan	Manufacture and selling of the chemical materials	37,474	37,474	318,216	21.99	530,905	216,588	-	Equity method (Note1)
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Chemical Synthesis & Biotech Co., Ltd.	Taiwan	Manufacture and selling of the chemical materials	563,849	563,849	21,575,064	28.05	926,769	132,128	-	Equity method (Note1)
China Chemical & Pharmaceutical Co., Ltd.	PHERMPEP CO., LTD.	Taiwan	Wholesale of biotechnology services and health products.	54,480	54,480	2,483,250	31.04	6,007	(3,077)	-	Equity method (Note1)
Chunghwa Yuming Healthcare Co., Ltd.	Chunghwa Biomedical Technology Corp.	Taiwan	Manufacturer of cleaning products	17,680	17,680	1,768,000	75.23	20,330	(1.872)	-	Sub-subsidary (Note 1)
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Chung-Hwa Le Huo Jian Kang (HK) Co., Ltd.	Hong Kong	Biotech products sold as an agent	-	-	-	100.00	-	-	-	Sub-subsidary (Note 1)

Note 1: The Company does not recognize investment profit and loss directly.

Note 2: For the relevant information about the significant deals of the investees; please see attached table 1-6.

Cenra Inc. and subsidiaries
Basic information- Information of the investees in China
January 1 to March 31, 2026

Attached table 8 Unit: NTD thousand
(Except where otherwise stated)

Names of investees in China	Principal business	Paid-in shares Capital	Mode of investments (Note 1)	Accumulated amount of investment remitted from Taiwan at beginning	Amount of investment remitted or recovered in current period		Accumulated amount of investment remitted from Taiwan at ending	Current period profit / loss of the investee	The Company's directly or indirectly invested shareholding	Investment Profit or Loss for Current Period (Note 2)	Book value of investment at ending	The investment income received at the end of the current period	Remarks
					Outward remittance	Recover							
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Manufacture and sales of pharmaceutical medicine and health products.	\$ 755,151	2	\$ 768,672	\$ -	\$ -	\$ 768,672	\$ 28,493	100	\$ 28,493	\$1,275,054	\$ 472,412	Note 1 (2), Note 2(2) B
Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd.	Wholesale and sales of pharmaceutical medicine and medical equipment.	132,149	3	-	-	-	-	(7,266)	100	(7,266)	(26,286)	-	Note 2(2) C, Note 3
Shanghai Yuhou Trading Co., Ltd. (formerly known as Pei Fu (Shanghai) Co., Ltd.)	Wholesale and sales of medical equipment.	200,070	3	-	-	-	-	(2,545)	100	(2,545)	4,537	-	Note 2(2) C, Note 4
Suzhou Chung-hwa Le Huo Jian Kang Co., Ltd.	E-commerce sales of health products	87,156	3	-	-	-	-	(2,417)	100	(2,417)	20,676	-	Note 2(2) C, Note 5
Wuxi Jirui Medical Technology Co., Ltd.	Production and sales of APIs	23,451	3	-	-	-	-	(24)	34	(8)	1,988	-	Note 2(2) C, Note 6

Company name	Accumulated investment from Taiwan to Mainland China at ending	Amount of investment approved by Investment Commission of MOEA	Investment amount approved by the Investment Commission MOEAIC
China Chemical & Pharmaceutical Co., Ltd.	\$ 296,260	\$ 769,143	\$ 4,278,531

Note 1: There are three types of investments labeled by the respective number:

- (1) Direct investment in Mainland China.
- (2) Indirect investment in Mainland China through a third country (please specify the investment company in the third country):
Investment in Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd. through Chunghwa Holding Co., Ltd.
- (3) Other ways.

Note 2: Recognized as gains or losses on investment in current period:

- (1) Please note if the investee is still under preparation and there was no investment gain or loss.
- (2) The basis of recognition of investment income is classified into following three types, which should be marked out.
 - A. Financial statements audited and audited and attested by an international accounting firm that has a cooperative relationship with a certified public accounting firm registered in the Republic of China.
 - B. Financial statements audited by the CPAs who audit the parent company in Taiwan.
 - C. Others.

Note 3: Direct investment with RMB 30,000 thousand by Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.

Note 4: Up to 100% equity of Shanghai Yuhou Trading Co., Ltd. (formerly known as Pei Fu (Shanghai) Co., Ltd.) was purchased with a fund of RMB 1,797 thousand from Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd. in June 2016. In 2023, a total of RMB 41,278 thousand from Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd. was used for direct investment.

Note 5: Direct investment with RMB 20,000 by Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial CO., LTD

Note 6: Acquired 34% shareholding of Wuxi Jirui Medical Technology Co., Ltd. by use of RMB 1,802 thousand capital from The Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd.